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Liyang Zhao: The role of acyl-CoA synthetase-mediated fatty acid metabolism in metabolic 
myopathy and atherosclerosis 
(Under the direction of Rosalind A. Coleman) 
Long chain acyl-CoA synthetases (ACSLs), and very long chain acyl-CoA synthetases 
(ACSVLs) which are also known as fatty acid transporters (FATPs), initiate long chain fatty acid 
(LCFA) oxidation through activation of LCFA by thiol-esterification.  
Impaired fatty acid oxidation (FAO) can cause metabolic myopathy; however, the 
underlying mechanisms by which FAO impairment contributes to the pathogenesis of myopathy 
remain obscure.  Compared to control mice (Acsl1flox/flox), Acsl1M-/- mice had 3.4- and 1.5-fold 
higher plasma creatine kinase (CK) and aspartate aminotransferase (AST) activities, suggesting 
muscle damage.  Gastrocnemius from Acsl1M-/- mice showed central nuclei, a marker of muscle 
regeneration. The expression of caspase-3 protein exclusively in Acsl1M-/- muscle suggested 
muscle regeneration. After endurance exercise, compared to control mice, the rate of new protein 
synthesis was 2.1-fold higher, and the phosphorylation of pS6K was 2.5-fold higher in glycolytic 
muscle from Acsl1M-/- mice. These results suggested an increased need to resynthesize protein 
that had been degraded to supply amino acids for fuel.  Additionally, loss of ACSL1 promoted an 
increase in mitochondrial biogenesis while impairing mitochondrial structure in gastrocnemius.  
FATP1 is necessary to maintain the oxidative and anti-inflammatory phenotype in 
macrophages. Macrophages play multifaceted roles in atherogenesis, but the effect of 




FATP1 limits macrophage-mediated inflammation during atherogenesis, bone marrow collected 
from Fatp1+/+ or Fatp1-/- mice was transplanted into Ldlr-/- mice, and chimeric mice were fed a 
Western-Diet for 12 weeks. Compared to Fatp1+/+Ldlr-/- mice,  Fatp1-/-Ldlr-/- mice exhibit larger 
lesions and evidence of elevated oxidative stress and inflammation in the atherosclerotic plaque 
without systemic alterations in plasma cholesterols, suggesting that the effect is localized to the 
cells of the vessel microenvironment.  
This dissertation shows that two of the acyl-CoA synthetases are essential for maintaining 
normal skeletal muscle and macrophage fatty acid (FA) metabolism. Lack of ACSL1 led to an 
enhanced drain on amino acids by enhancing protein synthesis after exercise and increased 
mitochondrial biogenesis with disordered mitochondrial structure, which was partially 
responsible for the myopathy in Acsl1M-/- mice. FATP1-directed FA metabolism in macrophages 
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 LCFA can either be degraded by mitochondria via β-oxidation to generate ATP or 
incorporated into essential cellular components such as triacylglycerol (TAG) or phospholipid 
(1).  Before these steps can occur, LCFA must be ‘activated’ to long chain acyl-CoA by ACSLs 
or ACSVLs, which are also known as FATPs.  ACSLs and ACSVLs/FATPs are a group of 13 
proteins including three subfamilies: ACSL, ACSVL, and ACS bubblegum (ACSBg) (1). ACSLs 
prefer fatty acid (FA) substrates of 12-20 carbons, ACSVLs can activate FAs longer than 20 
carbons but prefer 16- and 18- carbon FAs, and ACSBgs use both long and very long chain FAs 
(1). ACSLs are composed of 5 family members including ACSL1, ACSL3, ACSL4, ACSL5, and 
ACSL6. Since first introduced by Kornberg and Pricer, ACSL1 has been the most studied ACSL 
isoform, and its roles in a variety of tissues have been extensively examined (2-6). In 1994, 
Schaffer and Lodish cloned a novel protein that they named “fatty acid transport protein” 
(FATP) due to its ability to mediate the uptake of LCFA across the plasma membrane (7). 
ACSVL was first purified and cloned in 1996 by Hashimoto (8-10). It was later found that FATP 
contains intrinsic ACSL/ACSVL enzyme activity, and is homologous to ACSVL(8).  Six 
ACSVLs/FATPs have been identified, and FATP1 has remained the most extensively studied 
isoform (11). Two mammalian ACSBgs had been identified (12,13). The ACSBg1 isoform 
activates both long- and very long- chain saturated and unsaturated FAs, and ACSBg2 activates 




normal cellular function. Deletion of Acsl1 has been linked to dysfunctions of heart, liver, and 
adipose tissue in mouse models, which will be discussed in next section (3,4,15). Mutation of 
ACSL4 causes an X-linked mental retardation syndrome in human (16). Lack of ACSL6 inhibits 
 proliferation of NB41A3 mouse neuroblastoma cells (17).  Deletion of macrophage Fatp1 
exacerbates high fat diet (HFD)-induced glucose intolerance in mice because the absence of 
FATP1 induces macrophage pro-inflammatory activation, which increases oxidative stress and 
inflammation in adipose tissue (18). Mutation of FATP4 in humans causes ichthyosis 
prematurity syndrome because FATP4 is expressed in epidermis, where FATP4 serves the 
important function of maintaining normal epidermal barrier properties. FATP4 whole body 
knockout mice die either in utero or the neonatal period due to malformed skin resulting in 
impaired skin barrier function, and severe respiratory difficulties (19). Although the roles of 
ACSL1 and FATP1 have been extensively studied in heart, liver, and adipose tissue, their roles 
in other organs and cells are less well understood. ACSLs/ ACSVLs started LCFA metabolism 
through the action of thiol- esterification. LCFA is a major energy source and dysregulation of 
LCFA metabolism is linked to metabolic diseases (20,21); therefore, activation of LCFA by 
ACSLs/ACSVLs is critical for pathways of LCFA metabolism.   The purpose of this dissertation 
is to expand our knowledge regarding the role of ACSL1 in skeletal muscle function and FATP1 
in macrophage function.  
Skeletal muscle is critical for supporting body posture, generating movement, and 
maintaining body temperature. The disorders of skeletal muscle fibers are defined as myopathies, 
which can impair an individual’s mobility and cause significant pain. Acquired myopathies in 
systemic disease can result from endocrinopathies, inflammatory disease, and drug- or toxin-




these mutations can damage fiber structure or impair muscle metabolism (22). One of the leading 
causes of myopathy are abnormalities in muscle cell metabolism.  Skeletal muscle exhibits 
plasticity and complexity in its choice of fuel substrate. During starvation, muscle initiates FAO 
to provide ATP and releases amino acids as the substrate for liver gluconeogenesis. During 
acute, intense exercise, muscle prefers to use glucose as its primary fuel, whereas during rest or 
prolonged exercise, muscle switches to use primarily fatty acids (23,24).  
Impairment of fatty acid metabolism, glycogen storage diseases, and mitochondrial 
disease, are three leading causes of metabolic myopathies (25,26). Thus, the first part of this 
dissertation will determine how reduced FAO, through muscle-specific deletion of Acsl1, affects 
muscle functions and what mechanism contributes to myopathy in a mouse model.  
Atherosclerosis is a chronic inflammatory disease of large- and medium- size arteries and 
a major cause of death (27). Atherogenesis is characterized by four major steps: 1) initiation of 
endothelial activation and inflammation; 2) promotion of intimal lipoprotein deposition, 
retention, modification, and foam cell formation; 3) progression of complex plaques by growth 
and enlargement of the necrotic core, fibrosis, thrombosis, and remodeling; and 4) precipitation 
of acute events such as myocardial infarction or ischemic stroke (28). An intervention study 
showed that after 5 years strict adherence to the diet, a 10%-fat vegetarian diet, accompanied by 
moderate aerobic exercise, stress management, and smoking cessation, decreases coronary 
diameter stenosis by 3.1 absolute percentage points (29). Studying the biological mechanisms of 
atherosclerosis can provide insight to better treat and prevent atherosclerosis. Macrophages play 
multifaceted roles in promoting lesion progression through secreting pro-inflammatory 
cytokines, matrix degrading enzymes, and reactive oxygen species (ROS), which all contribute 




understanding the phenotype of macrophages, the role of metabolism in regulating inflammation 
still remains unclear. Thus, the second part of this dissertation is aimed at investigating how 
reduced FA metabolism through macrophage-specific deletion of Fatp1 modulates atherogenesis 
in a mouse model.  
Long chain acyl-CoA synthetases 
 
LCFAs play critical roles in maintaining cellular homeostasis. The active form of LCFA 
is long-chain acyl-CoA, which serves as the substrate for anabolic pathways such as TAG, 
phospholipid, cholesterol ester (CE), and ceramide synthesis or for catabolic pathways such as β-
oxidation in peroxisomes and mitochondria and ω-oxidation in the endoplasmic reticulum (ER) 
to produce ATP. Also, acyl-CoAs regulate cell signaling, membrane permeability, and gene 
transcription (1,30,31). Acyl-CoAs, such as palmitoyl-CoA and myristoyl-CoA, function as 
precursors for protein acylation (1).   Both LCFA and acyl-CoA are ligands for transcription 
factors such as peroxisome proliferator-activated receptor PPARα, β, or , and hepatocyte 
nuclear factor 4 (HNF4α) (32).  By activating or suppressing gene expression, LCFA and acyl-
CoA can further influence metabolism. LCFAs can be obtained from the diet, produced by de 
novo synthesis, or lipolyzed from adipose tissue. Unesterified LCFA enters cell through both a 
passive flip-flop or through saturable, protein-mediated transport (33), and more than 90% of the 
LCFAs enter into tissues via the saturable pathway (33,34).  The formation of acyl-CoAs 
catalyzed by ACSLs traps the FA inside of the cell.  The two-step reactions catalyzed by ACSLs 







Figure. 1.1. ACSL catalyzes activation of LCFA. This activation step is catalyzed by acyl-
CoA synthetase (ACSL) via a two-step reactions: 1) the formation of an intermediate fatty acyl-
AMP with the release of pyrophosphate, and 2) the formation of a fatty acyl-CoA with the 
release of AMP (35,36).  
Mammalian cells express 5 ACSL isoforms. Although ACSL isoforms have an 
overlapping range of substrates, each isoform differs in substrate preference and enzyme 
kinetics(35). All ACSL isoforms activate FA of 12 to 22 carbons, and each ACSL isoform has 
distinct subcellular locations, and tissue-specific expression (31,37). ACSL1 is a 78 KD 
membrane protein localized in a variety of cellular compartments including ER, mitochondria, 
plasma membrane, and lipid droplets (38). ACSL1 mRNA and protein are highly expressed in 
oxidative tissues such as adipose tissue, liver, heart, and skeletal muscle (3,4,6,15,39). In heart, 
deletion of Acsl1 reduces more than 90% of FAO, indicating that ACSL1 is the predominant 
isoform in heart (3). Similarly, deletion of Acsl1 reduces FAO by 90% in gastrocnemius, a 
muscle type that contains mixed glycolytic and oxidative fibers, and by 72% FAO in soleus, a 
muscle comprising most of oxidative fibers (40).   These data suggest that ACSL1 is an essential 
enzyme for β-oxidation in both glycolytic and oxidative muscles. 
 
Fatty acid + ATP           acyl-AMP + PPi (pyrophosphate)      




Role of ACSL1 in an animal models 
  
ACSL isoforms differ in tissue distribution indicating that each may play a specific role 
related to a particular tissue(31). Knowledge of the tissue-specific distribution and contribution 
of ACSL1 proteins would provide information regarding the distinct role of ACSL1 in disturbed 
lipid metabolism (31). Mouse models with ACSL1 deficiency in specific organs allow us to 
define the exact role of ACSL1 in lipid metabolism and lipid signaling in targeted organs.   
Li et al. created liver-specific Acsl1 deficient mice (Acsl1L-/-) by crossing Acsl1flox/flox 
mice with rat albumin promoter-Cre transgenic mice (Alb-CreTg/0). Loss of ACSL1 decreases 
50% of total ACS activity and 35% of long-chain acyl-CoA content in liver but did not change 
body weight, organ weight, or adiposity. Although total liver TAG content remained the same, 
compared to controls, the incorporation of [14C] oleate into TAG was diminished in isolated 
hepatocytes from ACSL1 liver deficient mice. Despite the reduced acyl-CoA content in liver, 
Acsl1L-/- mice are not protected from HFD-induced hepatosteatosis and insulin resistance. 
Deletion of Acsl1 alters the distribution of specific FA in several phospholipid species. 
Compared with control mice, Acsl1L−/− liver phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) contain higher percentages of palmitate (C16:0); PC, PE, and 
phosphatidylserine (PS) contain lower percentages of oleate (C18:1) ; Lysophosphatidylcholine 
contains more C16:0 and C18:1 and less stearate (C18:0) and arachidonic acid (C20:4), 
suggesting that ACSL1 makes a specific contribution of 18:0-CoA and 20:4-CoA to 
phospholipid (6).  
White adipose tissue stores energy in the form of TAG, and brown adipose tissue plays a 
role in thermogenesis by oxidizing FA. To study the specific functions of ACSL1 in adipose 




Acsl1flox/flox mice with mice in which Cre expression is driven by the adipocyte protein-2 (aP2) 
promoter.  Loss of ACSL1 reduces total ACS activity by 80%, indicating that among 5 ACSL 
isoforms, ACSL1 contributes the most to ACS activity in adipose tissue. In differentiated 3T3-
L1 adipocytes, mRNA expression of Acsl1 increases 160-fold compared to undifferentiated cells, 
whereas the mRNA expression of the other Acsl isoforms remain unchanged suggesting that 
Acsl1 is upregulated during adipocyte differentiation (4,41,42).  However, rather than reduced fat 
mass and body weight, Acsl1A-/- mice have increased fat mass upon low fat diet (LFD) feeding 
and gain weight similarly to control mice upon HFD feeding. Compared to controls, the FAO 
rate is 50-90% lower, but FA incorporation rate is normal in isolated Acsl1A-/- adipocytes. 
Further, Acsl1A−/− mice are markedly cold intolerant. Collectively, these data show that adipose 
tissue ACSL1 mainly directs LCFA towards β-oxidation rather than TAG synthesis and storage 
(4).  
The mitochondrial oxidation of LCFA provides 60 to 90% of heart ATP (43). To 
understand the role of ACSL1 in heart, Ellis et al. generated mice deficient in ACSL1 globally 
(Acsl1T−/−) and mice deficient in ACSL1 specifically in heart (Acsl1H−/−) (3). Acsl1T−/− mice and 
Acsl1H−/− mice were generated by crossing Acsl1flox/flox mice with mice in which Cre expression is 
driven either by the ubiquitous promoter enhancer or by the myosin heavy chain promoter, 
respectively, both of which are induced by tamoxifen to generate tamoxifen-inducible whole 
body or heart-specific Acsl1 knockout mice (3).  Compared to controls, both total ACS activity 
and LCFA oxidation in Acsl1T−/− heart were reduced by 90%. Reduced FAO forces the heart to 
use more glucose, manifested by increased pyruvate and glucose oxidation. Increased glucose 
use activates mechanistic target of rapamycin complex 1 (mTORC1), which promotes RNA and 




phosphorylation of S6 kinase, a target of mTOR kinase in Acsl1T−/− and Acsl1H−/− heart, increases 
5-fold. Further, compared with controls, Acsl1T−/− heart contains 3 times more mitochondria that 
contain vacuoles, inclusions, or disrupted cristae.  Mitochondria from ACSL1-deficient hearts 
display reduced respiratory function, evident by consuming 35% or 43% less oxygen than 
controls after stimulation with ADP or the mitochondrial uncoupler FCCP. Treating mice with 
the mTORC1 inhibitor rapamycin, mitochondrial structure and function from Acsl1T−/− hearts 
return to normal. Loss of ACSL1 also diminishes the rate of autophagy in heart, and rapamycin 
treatment restores autophagy to a normal rate (5). Cardiolipin (CL) regulates mitochondrial 
function (45). Cardiac cardiolipin normally contains as much as 77% linoleate. Compared to 
control hearts, ACSL1-deficient hearts contains 83% less tetralinoleoyl-cardiolipin (CL). Despite 
normalization of the amount of tetralinoleoyl-cardiolipin in Acsl1T−/− heart when animals are fed 
an enriched-linoleate diet, this intervention did not improve mitochondrial respiratory function 
(44). Taken together, reduced FAO in ACSL1-deficient heart results in compensatory catabolism 
of glucose leading to mTOR activation, autophagy inhibition, and mitochondrial damage, which 
taken as a whole result in diastolic function (3,5).  
Mechanisms of muscle damage and regeneration 
 
Skeletal muscle uses glucose, FA, and amino acids as substrates for the production of 
ATP. At rest and during low-intensity sustained exercise, muscle prefers oxidative 
phosphorylation to generate ATP, and during high-intensity acute exercise, muscle favors 
glycolysis to produce ATP. While both FA and glucose can enter mitochondria for complete 
oxidation, skeletal muscle acquires most of its fuel from FA at rest and a combination of FA and 
glucose serves as the fuel during low to moderate-intensity exercise (46). Defects in energy 




radicals cause oxidative damage to cellular components such as DNA, lipid, and protein, which 
impair muscle cell function or even initiate muscle cell apoptosis (47,48). Inefficient transfer of 
electrons between the mitochondrial complexes is the primary source of ROS in cells, and 
defective energy production in metabolic myopathy may increase mitochondrial ROS 
production.  Mitochondria change morphology and number through fusion and fission as a 
consequence of muscle activity, and this morphology regulation is important to preserve muscle 
function. Under normal conditions, damaged mitochondria are removed by autophagy, which is 
critical in maintaining a healthy mitochondrial pool (49).  Consequently, autophagy inhibition is 
another potential underlying mechanism of metabolic myopathy. Indeed,  an autophagic defect is 
found in certain inherited muscle diseases such as congenital muscular dystrophy which is linked 
to mutations of genes coding for extracellular matrix proteins (50) and acute rhabdomyolysis 
caused by phosphatidic acid phosphatase/lipin-1 deficiency (51).   
Skeletal muscle is susceptible to injuries after direct trauma such as intensive physical 
activities or lacerations or resulting from indirect causes such as innate genetic defects and 
neurological dysfunction. These injuries, if left unrepaired, may lead to muscle cell death,  
muscle mass loss, locomotive deficit, and even lethality (52). Necrosis and apoptosis are two 
pathways of cell death. Necrosis is associated with conditions that lead to cell membrane 
damage, osmotic imbalances, cell swelling, and death. Necrosis accounts for numerous 
destructive changes associated with pathological conditions such as trauma, hypoxia, and energy 
deprivation. Apoptosis is important for normal development and tissue homeostasis(53). 
Apoptotic cell demonstrates unique structure change such as membrane blebbing, nuclear 
fragmentation, and formation of apoptotic bodies (53). These unique features distinguish 




because muscle cells are multinucleated, and they contain variable mitochondrial contents which 
are dependent on fiber type. Apoptosis caused muscle cell death can be found in numerous 
skeletal muscle disease (53).  For example, Mdx mice lack muscle dystrophin, and they have 
symptoms mimicking human Duchenne Muscular Dystrophy (DMD). Apoptosis is involved with 
muscle cell death in Mdx mice, and the presence of apoptosis is estimated between 0.5± 2% of 
total nuclei. Multiple chain acyl-CoA dehydrogenase deficiency (MADD) causes mitochondrial 
defects. Positive apoptotic nuclei have been found in the muscle biopsy specimen from MADD 
patients (54,55). Mitochondria are associated with apoptosis for two reasons. First, the space 
between outer and inner mitochondrial membrane contains several pro-apoptotic proteins which 
can activate apoptosis pathway after released into the cytosol.  Second, mitochondria are the 
major organelle for ROS production.  ROS can directly induce the release of cytochrome C from 
mitochondria to cytosol. ROS also indirectly affects the apoptotic pathway by activating 
transcription factors, which induce both anti-apoptotic and pro-apoptotic gene expression (53). 
 
The presence of muscle satellite cells distinguishes skeletal muscle from heart by 
allowing skeletal muscle to regenerate (56).  Actually, skeletal muscle has a robust ability to 
initiate a rapid and extensive repair process (52). Muscle regeneration is characterized by a 
degenerative phase and a regenerative phase. The initial event of muscle degeneration is the 
damage or death of the muscle fibers. Myofiber sarcolemma disruption results in increased 
myofiber permeability, causing the leak of cytosol proteins, such as CK, into the blood. Serum 
CK is a biomarker of degenerative muscle disease and also can be observed after extensive 
physical exercise. The initial injury phase is followed by the activation of a muscle repair and 
proliferation process. Normally absent in muscle, macrophages quickly infiltrate the injured site 




myogenic cells. Muscle regeneration requires upregulation of transcription factors MyoD and 
Myf5.  Myoblasts contain transcription factors MyoD and/or Myf5. After stimulation,  myoblasts 
can differentiate into myocytes that express muscle-specific genes such as myosin heavy chain 
(Mhc) and muscle CK (52).  On muscle histology, newly formed muscle cells with small caliber 
and central nuclei are important morphological characteristics of muscle regeneration(52).  
Each skeletal muscle cell has multi-nuclei, and their nuclei are peripherally located, while 
cardiomyocytes are mono-nucleated, and the nucleus is in the center (57). Under normal 
condition, myonuclei are located in the periphery of the muscle fibers, while under certain 
pathological conditions, myonuclei migrate to the center of the myofibers. Therefore, a central 
nucleus is a common morphological marker for myopathies and is widely used in basic research 
as well as in diagnosis of myopathies in striated muscles (57,58). “While central nucleus is a 
biomarker of muscle regeneration, centronuclear myopathy represents a special group of 
inherited diseases in which the majority of muscle fibers have central nuclei due to structural 
protein derangement ” (58,59).  All centronuclear myopathies share certain pathological 
characteristics, including “(1) type I myofiber predominance and small fiber sizes, (2) abnormal 
NADH–tetrazolium reductase (NADH-TR) staining patterns, indicative of mitochondrial 
abnormalities; and (3) absence of necrosis, myofiber death, or regeneration” (59). These unique 
properties distinguish centronuclear myopathy from other muscle diseases, in which central 
nucleus is a sign of muscle regeneration.  
Lipid metabolism and metabolic myopathy 
 
Metabolic myopathy arises from inherited energy production defects in muscle. The 
symptoms and signs of metabolic myopathy include fatigue, weakness, myalgia, and muscle 




activities (60). Limitations in physical activity and muscle pain have negative impacts on 
patients’ lives; however, the mechanistic links between the metabolic defects and muscle injury 
are not well studied. Metabolic myopathies are comprised of 3 main categories of inborn error 
diseases including mitochondrial myopathies,  glycogen storage diseases (GSDs), and defects in 
FAO (46). During exercise, patients with metabolic myopathies present with symptoms such as 
premature fatigue, episodic aches, and cramps. Each type of metabolic myopathy demonstrates a 
distinct pattern of exercise intolerance. For instance, GSDs result in high-intensity exercise 
intolerance, and defects in FAO and the mitochondrial myopathies lead to endurance exercise 
intolerance. Although metabolic myopathies are rare genetic disease, they are common causes of 
exercise-induced rhabdomyolysis (46). Biochemical assays, blood tests (serum CK activity, 
aspartate aminotransferase activity, and acylcarnitine profile.), muscle biopsy (light and electron 
microscopy), exercise testing, and genetic testing collectively help to determine the exact cause 
of the metabolic myopathy(46).  
Lipid metabolism defects also include failure of lipid droplet hydrolysis and impaired 
FAO. Failure of lipid droplet hydrolysis results from mutations of the adipose triacylglycerol 
lipase (ATGL) gene. Common FAO defects include primary carnitine deficiency, carnitine 
palmitoyltransferase 2 (CTP2) gene mutation, medium-chain acyl-CoA dehydrogenase (MCAD) 
deficiency, and very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD) (61-63).  
Carnitine palmitoyltransferase 1 (CPT1), an outer mitochondria membrane protein, 
catalyzes the formation of acyl-carnitine from long-chain acyl-CoA and carnitine. CPT2, located 
on the inter mitochondria enzyme, converts acyl-carnitine to acyl-CoA again, facilitating the 
entrance of LCFA from cytosol to mitochondrial matrix.  DiMauro first reported CPT2 




associated with 3 distinct presentations in humans:  a myopathic adult onset form with recurrent 
myoglobinuria, a life-threatening infantile form with hepatic, muscular, and cardiac involvement, 
and a fatal neonatal form with organ abnormalities (64).  In the CPT2 deficient mouse model, 
LCFA oxidation is significantly reduced in both heart and muscle, but TAG content increases 
only in heart and remains the same as controls in gastrocnemius or soleus (65).  
MCAD catalyzes the breakdown of C4 to C12 fatty acids. MCAD deficiency is the most 
common disorder of mitochondrial β-oxidation, and inherited in an autosomal recessive fashion, 
with an incidence of 1:27400 to 1:38000 in northern Europe (66).  MCAD total body knockout 
mice (MCAD-/-) develop organic aciduria, fatty liver, sporadic cardiac lesions, and profound cold 
intolerance after fasting. Importantly, MCAD-/- pups have a high mortality rate, demonstrating its 
importance and similarities to MCAD-deficient patients. (67). 
VLCAD catalyzes the first of four sequential reactions of the mitochondrial β-oxidation 
of LCFA such as palmitate (C16) and oleate (C18:1).  Deficiency of VLCAD is an autosomal 
recessive disorder with an incidence of 1:50,000 to 1:100,000 (68). Clinical presentations include 
hypoketotic hypoglycemia, cardiomyopathy, and rhabdomyolysis. Mice deficient in VLCAD 
(VLCAD-/-) demonstrate impaired metabolic homeostasis, hepatosteatosis, cold and fasting 
intolerance, and increases in acylcarnitine metabolites (69). Although VLCAD-/- mice have 
impaired mitochondrial FAO, they are protected from HFD-induced insulin resistance (70). After 
feeding mice either a HFD or a high carbohydrate-low fat diet, compared to controls, gene 
expression of the oxidative muscle fiber marker, Troponin I, is significantly increased in 
VLCAD-/- white muscle fibers, indicating that both diets induce an adaptation towards oxidative 




Very long chain acyl-CoA synthetases/Fatty Acid Transporter Proteins  
 
Protein-mediated transport of LCFA has been proposed to be the primary mode of LCFA 
uptake and activation. Several membrane proteins have been implicated in LCFA uptake, 
including fatty acid translocase (FAT)/CD36, plasma membrane fatty acid binding proteins 
(FABPs), ACSLs, and ACSVLs/FATPs (71). Fatty acid transport proteins (FATPs) are a family 
containing 6 members (FATP1, FATP2, FATP3, FATP4, FATP5, and FATP6). They range from 
63-80 kDa and are integral membrane proteins with at least one transmembrane domain (7). 
Similar to ACSLs, ACSVLs/FATPs are proteins containing inherent ACS activities, which 
activate FA through thiol-esterification.  Activation of FA by thiol-esterification to acyl-CoA 
requires two steps which have been illustrated in Figure 1.1. ACSVLs/FATPs contain several 
distinct and highly conserved motifs.  Motif 1is within the putative AMP binding domain; the 
Signature motif is responsible for acyl chain length specificity, recognizing FAs with chain 
lengths of 20 carbons or longer; Motif 2, overlapping with the signature motif, is used by 
Watkins et al. to organize ACSVLs/FATPs into groups or subfamilies (36).  
Among members of the ACSVL/FATP family, FATP1 was the first to be identified. In 
1994, Schaffer et al. cloned this protein and named it fatty acid transport protein due to its ability 
to increase LCFA uptake into 3T3-L1 adipocytes (7,71). FATPs facilitate LCFA uptake through 
its acyl-CoA synthetase activity (11,71,72). Mutations in the yeast homolog of FATP1, result in 
reduced ACSVL activity (73). Overexpression of wild-type FATP1 in COS1 cells increases ACS 
activity, while mutation of a domain within FATP1 that is highly conserved in ACS proteins 
abolishes ACS activity (71,74).  While FATP isoforms have sequence similarities, the proteins 
are differentially expressed in a wide variety of tissues and cell types, including adipose tissue, 




FATP4 proteins are highly expressed in adipose tissue, skeletal muscle, and heart. FATP2 and 
FATP5 are the major forms expressed in liver. FATP3 protein is expressed at high levels in lung, 
adrenal, ovary, and testis. FATP6 mainly is expressed in heart (75-78).   
Role of FATP1 in animal models  
FATP1 is one of the most studied FATP family members since its identification (7,11). 
FATP1 is a 71KD plasma membrane protein, and the expression of FATP1 results in specific 
and saturable uptake of LCFA into cells such as adipocytes, cardiac myocytes, and skeletal 
muscle myocytes (7,79).  FATP1 shares sequence similarity with the family of ACSL (74,79). 
However, Triacsin C, a competitive inhibitor of ACSL1 and ACSL4 (35), is unable to inhibit the 
acyl-CoA synthetase activity of FATP1 (79).  Similar to the glucose transporter 4 (GLUT4), 
insulin induces FATP1 translocation from cytosol to plasma membrane in muscle and adipose 
tissue (80). Compared to control mice, mice lacking FATP1 globally have lower adipose tissue 
and skeletal muscle lipid accumulation, and loss of FAPT1 protects mice from HFD-induced 
obesity and insulin resistance (81). Other than adipose tissue, muscle, and liver, FATP1 is also 
expressed in macrophages (18). Macrophages store TAG and CE (82). Importantly, macrophages 
are anti-inflammatory when they primarily metabolize fatty acids (18). FATP1 macrophage-
specific null mice demonstrate reduced FAO and increased inflammatory responses in adipose 
tissue (18). Loss of FATP1 drives macrophage to a pro-inflammatory phenotype and aggravates 
adipose tissue inflammation; this exacerbates HFD-induced glucose intolerance in mice (18).  
The mechanisms underlying atherosclerosis 
 
Atherosclerosis is a chronic inflammatory disease affecting large-and medium-sized 




lipids, and necrotic cores (83).  Risk factors for atherosclerosis include obesity, decreased insulin 
sensitivity, smoking, hypertension, and elevated serum cholesterol and triglycerides (84).  
Investigating the underlying causative mechanisms that promote atherogenesis can provide 
insights into the effective prevention and treatment methods. 
Atherosclerotic lesion development is initiated by the deposition of cholesterol-rich and 
apolipoprotein B-containing lipoproteins, particularly LDL, in the subendothelial space of blood 
vessels. Physical interaction between LDL and proteoglycan causes accumulated LDL to remain 
in the subendothelial space. LDL retained within the intima can be chemically modified by 
oxidation, aggregation, enzymatic or non-enzymatic cleavage, and hydrolysis,  all of which can 
trigger local maladaptive responses to modified LDL (85).  Oxidized LDL is pro-inflammatory, 
which enables it to activate overlying endothelial cells to express cell adhesion molecules such as 
intercellular adhesion molecule (ICAM) and vascular cell adhesion protein (VCAM) and to 
secrete chemokines. Monocytes, attracted by activated endothelial cells are slowed down by 
rolling and stopped by attachment to the endothelial cells followed by transmigration to the 
subendothelial space. Upon stimulation by macrophage colony-stimulating factor (M-CSF) and 
other differentiation factors, monocytes differentiate into macrophages (86). Scavenger receptor-
mediated engulfment of oxidized LDL (oxLDL) transforms infiltrated macrophages to 
cholesterol-laden foam cells. The combination of macrophages taking up oxLDL through 
scavenger receptors and a lack of negative feedback keeps this engulfing process going non-stop. 
Eventually, accumulated cholesterol esters give the macrophage “foam cell” characteristics. 
When the intracellular cholesterol content exceeds the foam cell’s processing capacity, the foam 
cell undergoes apoptosis. High concentrations of cytokines such as TNFα, un-esterified 




stress all promote apoptotic processes (87). Apoptotic cells are readily cleared by macrophages 
through phagocytosis in the early lesions. However, with the progression of lesions, 
phagocytosis of dead cells by lesion macrophages substantially decreases. Non-cleared apoptotic 
cells succumb to secondary necrosis and release cellular material into the microenvironment to 
ultimately create the necrotic core, a hallmark of an unstable atherosclerotic lesion. Eventually, 
lesions become vulnerable, and hematoma-hemorrhage and thrombus ensue, often leading to 
lesion rupture, myocardial infarction, and death.   
Macrophage metabolism and atherosclerosis 
 
Atherosclerosis is a multi-factorial disease, and macrophages play critical roles in 
promoting lesion formation, progression, and aggravation, such as 1) being the precursors of 
foam cells; 2) secreting pro-inflammatory cytokines, chemokines, ROS, reactive nitrogen species 
(RNS), matrix degrading enzyme, and anti-inflammatory cytokines; 3) and contributing 
primarily to an unstable plaque through imbalanced apoptosis and efferocytosis (85).  Studying 
macrophage biology has become a primary interest in the field. A body of evidence has 
demonstrated that macrophages, a critical component of the innate immune system, contribute to 
chronic inflammation-related pathology including obesity, insulin resistance, and atherosclerosis 
(88,89).   
Substrate metabolism is one of the mechanisms that affect the macrophage inflammatory 
response. Although there has been substantial progress in understanding the inflammatory 
phenotype of macrophages in blood vessels, the role of metabolism in regulating inflammation is 
still poorly understood. Macrophages exhibit a diverse spectrum of metabolic characteristics (90-
98). M1 macrophages use primarily glycolysis, which is linked to the pro-inflammatory 




microbicidal and phagocytic properties (99-101). M2 macrophages predominantly rely on 
mitochondrial FA oxidation (18,101-107), and are associated with tissue homeostasis and 
resolution of the inflammatory response. The M1 macrophage has been reported to be associated 
with plaque progression, while the M2 phenotype is linked to reduced lesion size and plaque 
regression (108-114). MicroRNA-33 (miR-33) inhibits FAO and promotes macrophage M1 
polarization. Macrophage-specific Mir33 deletion increases oxidative respiration and induces an 
M2 macrophage–associated gene profile. Treatment of Ldlr-/- mice with miR-33 inhibitors causes 
an accumulation of anti-inflammatory M2 macrophages and inhibits the progression of 
atherosclerosis (113,115).  
Summary and Hypothesis 
 
Lipid metabolism is one of the three branches of fuel metabolism. Other than supplying 
ATP, lipid metabolism also produces essential cellular components and signaling molecules. 
Previous reports demonstrated that dysfunctional lipid metabolism impairs the function of both 
skeletal muscle and macrophages.   ACSL and ACSVL/FATP play regulatory roles in the 
coordination of downstream lipid metabolism. This dissertation focuses on the role of muscle 
ACSL1 in the pathogenesis of metabolic myopathy and the role of macrophage FATP1 in the 
pathogenesis of atherosclerosis. I provide strong evidence that ACSL1- and FATP1- directed 
lipid metabolism are critical in maintaining proper muscle and macrophage function. This 
dissertation also establishes the mechanistic links between lipid metabolism and myopathy and 
atherosclerosis.  
Chapter 2 Hypothesis: ACSL1-directed FAO is essential in sustaining muscle function, and 




AIM 1. Determine the effects of exercise on Acsl1M-/- mice  
We hypothesized that exercise aggravates metabolic myopathy. This aim assessed how 
deletion of Acsl1 affected voluntary running capacity and muscle strength and 
coordination.  
AIM 2. Determine how lack of ACSL1 causes muscle myopathy  
We hypothesized that deletion of Acsl1 impaired muscle mitochondrial function and 
promoted muscle fiber apoptosis. This aim examined muscle mitochondrial function and 
structure, and also assessed muscle apoptosis in Acsl1M-/- mice.   
AIM3. Determine the how lack of ACSL1 affects muscle fuel metabolism 
We hypothesized that lack of muscle ACSL1 increased muscle protein turnover. This aim 
examined muscle glucose use and protein turnover. 
Chapter 3 Hypothesis: lack of macrophage FATP1-mediated lipid metabolism promotes 
atherogenesis.  
AIM 1.  Determine the effects of FATP1- mediated substrate availability on atherogenesis. 
We hypothesized that mutated fatty acid metabolism due to the deletion of Fatp1 would 
promote atherogenesis.  This aim examined the atherosclerotic lesion size and composition 
in Fatp1-/-Ldlr-/- mice.  
AIM 2. Determine the mechanisms of FATP1-mediated substrate availability on atherogenesis. 
We hypothesized that lack of macrophage FATP1 would increase inflammation in lesions. 
This aim examined how fuel metabolism regulates ROS production and inflammatory 






Rationale for Chapter 2  
As the predominant isoform in skeletal muscle, ACSL1 plays an essential role in 
initiating mitochondrial β-oxidation (15). To investigate the role of ACSL1 in muscle, we 
created a skeletal muscle specific ACSL1 knockout mouse (Acsl1M-/-) (15). Deletion of Acsl1 
reduces FAO 90% in muscle and impairs the performance of endurance exercise in mice (15). 
We hypothesized that attenuated muscle FAO through deletion of Acsl1 causes a myopathy. 
Chapter 2 of this dissertation aimed to examine the extent and the mechanisms of ACSL1 
mediated FAO in myopathy through an in vivo animal study. Our work showed that loss of 
ACSL1 promoted muscle protein turnover and damaged mitochondria morphology, which 

















CHAPTER 2: COMPENSATORY PROTEIN TURNOVER IMPAIRS MUSCLE 
FUNCTION AND MITOCHONDRIAL MORPHOLOGY IN MUSCLE SPECIFIC 




Loss of skeletal muscle long chain acyl-CoA synthetase isoform-1 (ACSL1) reduces 
ACSL activity and fatty acid oxidation (FAO) 90% in skeletal muscle and causes exercise 
intolerance.  We hypothesized that ACSL1-directed FAO is essential for energy production in 
muscle.  To understand why loss of FAO causes a metabolic myopathy, we examined muscle 
function, muscle histology, the use of alternate fuels, and mitochondrial function and 
morphology. Compared to control mice (Acsl1flox/flox), Acsl1M-/- mice had 3.4- and 1.5-fold higher 
plasma creatine kinase (CK) and aspartate aminotransferase (AST) activities, suggesting that the 
absence of ACSL1 caused muscle damage. Gastrocnemius from Acsl1M-/- mice showed central 
nuclei, a marker of muscle regeneration. The expression of caspase-3 protein exclusively in 
Acsl1M-/- muscle suggested that cells were undergoing apoptosis. Additionally, loss of ACSL1 
promoted an increase in mitochondrial biogenesis while impaired mitochondrial cristae structure 
in gastrocnemius. These changes were more pronounced in glycolytic than oxidative muscle.  
Unlike loss of FAO in hearts that were deficient in ACSL1, ACSL1-deficient muscle did not 
increase glucose uptake, and pyruvate oxidation was similar in gastrocnemius homogenates 
                                                            





from Acsl1M-/- and control mice.  However in glycolytic muscle from exercised Acsl1M-/- mice, 
the rate of new protein synthesis was 2.1 fold higher, suggesting a higher protein turnover, and 
consistent with an increased use of cellular protein as an energy substrate.  These data support 




Skeletal muscle exhibits plasticity and complexity in its choice of fuel substrate. During 
starvation, muscle initiates FAO to provide ATP, and it releases amino acids as the substrate for 
liver gluconeogenesis. During acute, intense exercise, muscle prefers to use glucose as its 
primary fuel, whereas during rest or prolonged exercise, muscle switches to use primarily fatty 
acids (23,24).  Genetic defects in muscle FAO are a leading cause of metabolic myopathy (30), 
characterized by fatigue, muscle weakness, and muscle injury.  People with defective medium 
chain acyl-CoA dehydrogenase, very long chain acyl-CoA dehydrogenase, or carnitine 
palmitoyltransferase 2 have muscle weakness, myalgia, elevated serum CK and myoglobulin, 
and exercise intolerance (62-64,66,116).  These symptoms can be worsened by fasting or 
physical activity, but the mechanisms by which reduced FAO results in a myopathy are 
understudied. Mice lacking muscle carnitine palmitoyltransferase 1b (Cpt1bM-/-) develop 
myodegeneration and a gait disturbance (26). Lack of CPT1b inhibits mitochondrial FAO and 
promotes mitochondrial biogenesis and compensatory peroxisomal FAO and amino acid 
oxidation in muscle (26). Indeed, lipid metabolism plays multifaceted roles in maintaining 
normal muscle physiology and function (117).  Lipin-1/ phosphatidic acid phosphatase catalyzes 




rhabdomyolysis (51,118). In mice, lipin-1 critically regulates autophagy, and deletion of Lpin1 
causes severe rhabdomyolysis (51). 
FAO requires the activation of fatty acids by ACSL.  In highly oxidative tissues like 
heart, brown adipose, and skeletal muscle, the majority of acyl-CoAs are formed by ACSL1 
(3,4,119,120). Lack of ACSL1 in heart, for example, results in cardiomyopathy with a 95% 
reduction in FAO, altered mitochondrial phospholipid composition, and impaired mitochondrial 
morphology and function (3,44). In mice lacking ACSL1 in skeletal muscle (Acsl1M-/-),  muscle 
ACSL activity and FAO are 90% lower than in littermate controls, and severe hypoglycemia 
prevents Acsl1M-/- mice from sustaining endurance exercise (120). Additionally, Acsl1M-/- 
gastrocnemius muscle contains many central nuclei, and plasma CK is elevated (120). We 
hypothesized that defective FAO in Acsl1M-/- muscle and inadequate glucose availability would 
cause a compensatory increase in the use of amino acids for energy.  Our data revealed that 
deletion of Acsl1 resulted in multifaceted defects in skeletal muscle energy metabolism, and that 
the damage, surprisingly, was more pronounced in glycolytic than in oxidative fibers. Acsl1M-/- 
muscle had increased protein turnover, mitochondrial biogenesis, and impaired mitochondrial 
cristae structure.  
Methods 
 
 Animal studies-Studies were performed with approval and in accordance with the 
guidelines of the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill. Mice were housed in a climate controlled animal facility with ad libitum 
access to food and water. Littermate Acsl1flox/flox (6) mice served as controls. Acsl1M-/- mice were 
generated by crossing Acsl1flox/flox mice with mice expressing muscle-specific human skeletal 




Three to 4 month old mice were used for studies.  Voluntary exercise was measured as 
previously described with modification (121).  Briefly, mice (n=7) were housed in single cages 
with accessible individual running wheels for 14 consecutive days. Wheel-running activity was 
monitored and recorded at 1-min intervals/day. Running distance, average speed, maximal speed, 
and percent of time spent running and rest were calculated. Light cycle and dark cycle (720 
minutes) activity was analyzed separately.  Treadmill exercise was conducted to stress the mice 
for the measurement of protein synthesis rate.  Mice were acclimated on speed-controlled 
treadmill for 3 consecutive days as previously described (120). On the day of the experiment, 
mice were fasted for 2 hours and placed on the treadmill. Treadmill protocol was programed as 
total 45 minutes with details: 0-3 m/min for 30 seconds, 3-6 m/min for 90 seconds, 6-10 m/min 
for 90 seconds, 10 m/min for 900 seconds, 10-12 m/min for 60 seconds, 12 m/min for 1500 
seconds, and 12-0 m/min for 60 seconds (120).  Immediately after treadmill exercise, a surface 
sensing of translation (SUnSET) assay was performed to assess the rate of global  protein 
synthesis (122). Sterilized puromycin solution in water (0.04 µmol/g) was injected 
intraperitoneally (IP). Thirty min later, mice were anesthetized, and skeletal muscle was 
collected for western blot analysis. Wire hang grip test was performed to assess muscle strength 
and coordination. Individual mice were placed at the center of a large metal rat cage lid. Once 
the mouse had gripped the metal grid, the cage lid was inverted over a large foam pad and 
suspended 30 cm above the pad. The latency for the mouse to fall from the lid was recorded in 
seconds. Hanging was scored as follows: -4, falling from the lid within 30 seconds; -2, falling 
within 60 seconds or poor gripping, using the limbs or using 2 paws instead of 4 paws; 0, well-




 Metabolites-Mice were fasted for 4 h and blood was collected by retro-orbital bleeding. 
Plasma CK activity was measured by the CK Liqui-UV® test kit (Stanbio, catalog 2910). Plasma 
AST activity was measured by the Liquid AST Reagent Set (Thermo Fisher, catalog 23-666-
120). To measure glycogen, muscle was weighed and homogenized in 1 N HCl, a portion of the 
homogenate was saved for glucose measurement. Glycogen was measured by acid hydrolysis 
method (15). Glucose was measured by Autokit Glucose (Wako Diagnostics, catalog 997-
03001). Muscle lipid was extracted by Folch method (123). TAG content was measured 
colorimetrically (Sigma, Catalog T2449). 
Biochemical Measurement- FAO was performed as described previously (3). Briefly, 
muscle was minced and homogenized in ice-cold buffer (100 mM KCl, 40 mM Tris-HCl, 10 mM 
Tris base, 5 mM MgCl2, 6H2O, 1 mM EDTA, and 1 mM ATP [pH 7.4]) at a 10-fold dilution 
(wt/vol). Oxidation was measured for 30 min in a 200 µl reaction mixture containing 100 mM 
sucrose, 10 mM Tris-HCl, 10 mM KPO4, 100 mM KCl, 1 mM MgCl2, 1 mM L-carnitine, 0.1 
mM malate, 2 mM ATP, 0.05 mM coenzyme A, and 1 mM dithiothreitol (pH 7.4) with palmitate 
or pyruvate as substrate. Either the production of 14C-labeled CO2 plus acid soluble metabolites 
(ASM) or only the production of 14C-labeled CO2 was measured. To measure glucose uptake, 
mice were placed at 4°C for 2 h, and then were injected retro-orbitally with 10 µCi [1-14C] 2-
deoxyglucose in saline. Skeletal muscles were harvested and snap frozen in liquid N2. 
Radioactivity was measured in tissue homogenates, and result was normalized to the 
radioactivity in 10 µl of serum collected 5 min after injection (3).   
ACSL Activity-Muscle ACSL specific activity was measured as described (5).  Briefly, 
tissue homogenates were centrifuged at 33,000 rpm for 1 h at 4°C to isolate total membrane 




7.4, 10 mM ATP, 250 mM CoA, 5 mM DTT, and 8 mM MgCl2 at room temperature for 10 min. 
The enzyme reaction was stopped with 1 ml of Dole’s solution (heptane: isopropanol: 1M 
H2SO4; 80:20:1, v/v).  Heptane and water were added to separate phases. Radioactivity of the 
acyl-CoAs in the aqueous phase was measured. 
Immunoblots- Muscles were homogenized in lysis buffer (20 mM Tris, 1% Triton X-
100, 50 mM NaCl, 250 mM sucrose, 50 mM NaF, 5 mM Na4P2O7, and a protease and 
phosphatase inhibitor cocktail (Thermo Fisher, catalog 78422)) with a motor-driven Teflon-glass 
homogenizer (Potter-Elvehjem, Pro Scientific Inc., Oxford, CT). Total protein lysate was 
collected by centrifuging the homogenate at 700 x g for 5 min. Protein concentrations were 
measured by the BCA protein assay (Thermo Fisher, catalog 23225). Primary antibodies were 
obtained: Caspase-3 (Cell Signaling Technology, #9662), ACSL1 (Cell Signaling Technology, 
#4047), GAPDH (ABCAM, ab8245), puromycin (Millipore Sigma, MABE343), VDAC 
(Abcam, 15859), LC3 (Sigma, L7543), and P62 (Abnova, H00008878-M01). 
Histology-Muscles were either snap frozen in liquid nitrogen-cooled isopentane or fixed 
in 10% neutral buffered formalin for paraffin embedding (FFPE). Muscle tissues were sectioned 
by the Histology Research Core Facility at UNC-Chapel Hill. For succinate dehydrogenase 
staining (SDH), frozen sections were incubated with working reagents containing 0.0065% 
KCN, 0.185% EDTA, 0.1% nitroblue tetrazolium, and 50 mM sodium succinate for 3 min in a 
37°C incubator. Tissue sections were then washed with dH2O and acetone, and mounted with 
Shandon™ Immu-Mount™ (Thermo Fisher, # 9990402). For Oil red O staining (ORO), frozen 
sections were incubated with freshly prepared ORO working solution (0.5% ORO in isopropanol 
diluted in water at a 3:2 ratio) for 15 min at room temperature. Tissue sections were rinsed with 




Immu-Mount™.  FFPE sections were stained with anti-cleaved caspase-3 for apoptosis, anti- 
phospho-Histone H3 (Ser10) for mitosis, anti-F4/80 for macrophage infiltration. The antibodies 
used for immunostaining were cleaved caspase-3 (1:1000 dilution) (Cell Signaling, 9661S), 
phosphor-histone H3 (1:400 dilution) (Cell Signaling, 9701S), and F4/80 (1:200 dilution) (AbD 
Serotec/BioRad, MCA497). Immunohistochemistry and H&E staining were performed by the 
UNC Histology Research Core Facility. All slides were scanned through Aperio digital scanner. 
Image J software was used to quantify the percentage of oxidative fibers. To quantify central 
nuclei, 4 different areas from the gastrocnemius (approximately 2000 muscle fibers in total) and 
an entire soleus section were examined to determine the percentage of cells containing central 
nuclei.  
Electron microscopy- Electron microscopy was performed by the UNC Microscopy 
Service Laboratory as previously described (5). Mice were fasted for 4 h, gastrocnemius and 
soleus were perfused and fixed with fresh 2.5% glutaraldehyde, 2% paraformaldehyde in 0.15 M 
sodium phosphate buffer, pH 7.4.  
Analysis of gene expression and mitochondria copy number- Skeletal muscle total RNA 
was extracted with RNeasy Plus Mini Kit (Qiagen, Catalog 74134).  DNA was isolated with 
DNease Blood & Tissue Kit (Qiagen, Catalog 69504).  cDNA was reverse transcribed with 
iScript cDNA Synthesis Kit (Bio-Rad, 1708890). cDNA and DNA were amplified with iTaq™ 
Universal SYBR® Green Supermix (Bio-Rad, 1725121). Sequences of primers used in this study 
are listed in the supplemental Table 1. The expression of target genes was normalized to the 
expression of 18S gene. Mitochondrial DNA gene NADH dehydrogenase 1 was normalized to 
nuclear DNA gene H19, and the ratio of mitochondrial DNA copy number / nuclear DNA copy 




Mitochondria studies- To isolate mitochondria, gastrocnemius was minced at least 200 
times in ice cold isolation buffer (70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM 
EGTA, and 0.5% (w/v) fatty acid free BSA) immediately after dissection. Minced muscle was 
homogenized in a motor-driven Teflon-glass homogenizing vessel with 10 up-and-down strokes. 
The homogenate was centrifuged at 700 x g for 5 min at 4°C in order to remove unbroken cells 
and nuclei. The supernatant was centrifuged at 10,000 x g for 10 min at 4°C to pellet 
mitochondria. To measure mitochondrial protein concentration and total mitochondrial protein 
amount, mitochondria were suspended in 100 µl isolation buffer without BSA to avoid 
interference with protein assay. The mitochondrial suspension was centrifuged for a second time 
at 10,000 x g for 10 min at 4°C after protein concentration was measured. The mitochondrial 
pellet was resuspended in assay buffer containing 70 mM sucrose, 220 mM mannitol, 10 mM 
KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA, and 0.2 w/v fatty acid-free BSA.  
Mitochondrial oxygen consumption rate (OCR) was measured with a Seahorse XF96 Analyzer 
with 5 mM pyruvate and 5 mM malate as complex I substrates, and 10 mM succinate plus 2 µM 
rotenone as complex II substrate. Mitochondria (4 µg of protein) were stimulated in succession 
with 100 mM ADP, 1 mg/ml oligomycin, 4 mM carbonyl cyanide-4-(trifluoromethoxy)-
phenylhydrazone (FCCP), and 4 mm antimycin A, all of which were dissolved in assay buffer 
without BSA to avoid port injection failure (5). Mitochondrial outer membrane integrity was 
assessed by Cytochrome c Oxidase Assay Kit according to the protocol (MilliporeSigma, 
CYTOCOX1) 
Results   
 
 Fatty acid use and ACSL activity were reduced in muscle from Acsl1M-/- mice.  ACSL1 




confirming the tissue specificity of the knockout (Fig. 1A). Acsl3 mRNA was 1.5-fold higher in 
Acsl1M-/- gastrocnemius than in controls (120).  Similar to the expression of Acsl isoforms in 
heart that is deficient in ACSL1 (5,120), compared to controls, Acsl3 mRNA was 3.4-fold higher 
in Acsl1M-/- soleus (Fig. 1B). However, despite the increase in Acsl3 mRNA in Acsl1M-/- muscle, 
total ACSL activity was almost 90% lower in both glycolytic (white gastrocnemius) and 
oxidative muscles (red gastrocnemius and soleus) from Acsl1M-/- mice, indicating that 
compensation by ACSL3 was minimal (Fig. 1C). Similarly, loss of ACSL1 reduced the rate of 
FAO by 77, 90, and 72%, respectively, in white and red gastrocnemius and soleus. The reduction 
in FAO was more pronounced in gastrocnemius, which is a muscle with mixed fiber types, than 
in soleus which contains primarily oxidative fibers (Fig. 1D).  
Despite reduced FAO, carbohydrate use did not increase in Acsl1M-/- muscle.  As in the 
Cpt1bM-/- mouse, the reduction of FAO in Acsl1M-/- mouse did not alter TAG content in 
gastrocnemius, but resulted in a 2.5 fold increase in soleus TAG content, although FAO was least 
affected in soleus (Fig. 2A) (26). ORO and SDH staining indicated that in Acsl1M-/- mice, lipid 
droplets were more prominent in soleus than in gastrocnemius, particularly in type I fibers (Supl. 
Fig. 1).    Because FAO is 72-90% lower in Acsl1M-/- muscle, we hypothesized that glucose use 
would increase to compensate, as occurs in hearts lacking ACSL1 (3). Supporting this 
hypothesis, under fed conditions, glycogen content from Acsl1M-/- muscle was approximately 
50% lower in oxidative muscles than controls but was unchanged in glycolytic white 
gastrocnemius (Fig. 2B). These data suggested that the reduced FAO in Acsl1M-/- skeletal muscle 
enhanced the use of glucose. Decreased glycogen content can result either from increased 
glucose use or reduced glycogen synthesis. To determine whether muscle had increased glucose 




deoxyglucose during shivering thermogenesis which promotes muscle glucose uptake (125).  
Mice were placed at 4°C for 2 h, and the glucose uptake assay was performed while mice were 
shivering. Unexpectedly, the deletion of Acsl1 did not increase skeletal muscle glucose uptake 
(Fig. 2C). To assess whether the deletion of Acsl1 accelerated muscle tricarboxylic acid (TCA) 
flux, [2-14C] pyruvate oxidation was measured. Consistent with the lack of enhanced uptake of 
glucose, no difference in pyruvate oxidation was observed between genotypes (Fig. 2D). 
Similarly, mRNA expression of pyruvate dehydrogenase subunit I (Pdha1) and citrate synthase 
(Cs) did not change (Supl. Fig. 2A).  A hyperinsulinemic-hyperglycemic clamp with excess 
glucose at ~225 mg/dl (Fig. 2E), showed lower whole body glucose uptake and glucose infusion 
rate in Acsl1M-/- mice than in controls (Fig. 2F, G, H).  These data indicate that when surplus 
glucose was provided, insulin sensitivity was reduced in Acsl1M-/- mice.  Taken together, the data 
suggest that although loss of ACSL1 reduced FAO in skeletal muscle, muscle glucose use did 
not increase.  
Loss of ACSL impaired voluntary running capacity and muscle strength. When mice 
are forced to run on a treadmill, control mice ran about 3000 meters whereas Acsl1M-/- mice ran 
only 1500 meters before plasma glucose concentrations dropped to 40 mg/dl (120). During low 
intensity or prolonged exercise, skeletal muscle primarily oxidizes fatty acid to generate ATP 
(126). Because Acsl1M-/- mice had impaired endurance exercise capacity, we asked whether the 
reduction in FAO would affect the voluntary running capacity. When Acsl1M-/- mice were 
allowed to use voluntary running wheels for 2 weeks, Acsl1M-/- mice ran 21% less than control 
mice in total distance (Fig. 3A).  Mice are nocturnal animals and most active in the dark; thus, 
the average and maximal dark cycle running speeds of Acsl1M-/- mice were slower than controls, 




speed, but the non-running times (break times) during the dark cycle were also significantly 
lengthened on days 2, 3, and 7 (Fig. 3D), although no genotype difference was observed when 
total non-running times were summed (Fig. 3E).  No differences between genotypes were 
detected in average speed, maximal speed, or non-running times during the light period (Supl. 
Fig. 3A-C). To test muscle strength and coordination, a wire hang grip test was performed in 
mice 8 to 11 weeks old. Lack of ACSL1 impaired overall muscle strength (Fig. 3F).     
Deletion of Acsl1 caused myopathy. CPT1b directs the entry of long chain acyl-CoAs 
from cytosol into the mitochondria matrix to initiate β-oxidation, and Cpt1bM-/- mice demonstrate 
myodegeneration and impaired exercise performance (26). Because ACSL1 also plays a pivotal 
role in regulating FA ß-oxidation, we questioned whether loss of ACSL1 would similarly cause 
muscle damage. Compared to control mice, biomarkers of skeletal muscle damage, CK and AST 
activities were 3.5-fold and 1.54-fold higher, respectively, in Acsl1M-/- mice, suggesting that lack 
of ACSL1 caused muscle cell injury (Fig. 4A, B). Unlike cardiac muscle, skeletal muscle is able 
to regenerate after it has been damaged, and the presence of central nuclei indicates muscle 
regeneration (127). Although muscle showed no signs of necrosis after deletion of Acsl1, 8.25% 
of Acsl1M-/- gastrocnemius cells contained central nuclei, compared to only 0.79% of cells in 
control gastrocnemius (Fig. 4C, E). Since exercise aggravates metabolic myopathies, by 
increasing energy stress, we assessed the effects of voluntary running on muscle histology (128). 
Compared to resting mice, voluntary running increased the number of central nuclei by 1.8 fold 
in Acsl1M-/- mice, whereas no change in the number of central nuclei was observed in littermate 
controls. In contrast to the gastrocnemius, few cells in Acsl1M-/- soleus contained central nuclei at 
either rest or after exercise, indicating that the deletion of Acsl1 had a greater impact on 




phospho-histone H3 indicated that the central nuclei were indeed caused by regeneration (Supl. 
Fig. 4). In addition, compared to controls, the expression of the muscle regeneration markers 
MyoG and MyoD in Acsl1M-/- white gastrocnemius were 2.2- and 1.7-fold higher, but lower in 
Acsl1M-/- red gastrocnemius indicating that regeneration occurred exclusively in glycolytic 
muscle. In contrast, no differences were found in soleus expression of MyoG or MyoD (Fig. 4H). 
Taken together, these results support the conclusion that ACSL1-directed FAO is required to 
maintain normal muscle homeostasis.  
Apoptosis occurred in Acsl1M-/- muscle. Central nuclei occur by either necrosis or 
apoptosis during processes of muscle death and regeneration. Because muscle histology revealed 
no evidence of necrosis, we examined caspase-3 to determine whether apoptosis had played a 
role in Acsl1M-/- mice.  Caspase-3 and its cleaved form were examined by western blot and 
immunohistochemistry (129).  Caspase-3 protein is not observed in skeletal muscle from healthy 
adult mice; thus, the appearance of caspase-3 in Acsl1M-/- gastrocnemius strongly suggested that 
apoptosis was occurring (Fig. 5A) (130).  Despite the presence of full-length caspase-3, we could 
not detect cleaved caspase-3 in muscle homogenates by western blot; however, 
immunohistochemistry showed occasional positive cleaved caspase-3 staining in gastrocnemius 
(Fig. 5B). In addition, positive staining of the macrophage surface marker F4/80 in Acsl1M-/- 
gastrocnemius (Fig. 5C), in the absence of  expression of the inflammatory markers IL1, IL6, 
and TNF-α, supported the idea that macrophages were phagocytosing muscle cells that had died 
via apoptosis (Supl. Fig. 5A, B). 
Deletion of Acsl1 resulted in mitochondrial biogenesis and oxidative fiber switch.  In 
contrast to cardiac ACSL1 which prefers linoleate (18:2) as a substrate (44), muscle ACSL1 




Similar to heart, ACSL1 was enriched in mitochondrial membranes compared to the homogenate 
(Fig. 6B, C). ER fractions showed comparatively low amounts of ACSL1, but the presence of 
VDAC in the ER fraction indicated considerable mitochondrial contamination (data not shown). 
To assess the effect of ACSL1 loss on mitochondrial number, we measured mitochondria gene 
copy by quantifying the ratio of DNA copy number of   NADH dehydrogenase 1 to the nuclear 
gene H19 (124). Compared to controls, Acsl1M-/- white gastrocnemius had 1.5-fold higher 
mitochondrial content, but no difference in red gastrocnemius or soleus (Fig. 6D). Similar to the 
Cpt1bM-/- mouse (26) , the expression of mitochondrial FAO genes in gastrocnemius (Fig. 6E) 
but not soleus (Fig. 6F) increased coordinately, suggesting that loss of ACSL1 and diminished 
FAO promoted a compensatory increase in FAO capacity.  Confirming the increase in 
mitochondrial density, the inner mitochondrial enzyme SDH in Acsl1M-/- gastrocnemius was 1.5-
fold higher than in control myofibers (Fig. 6G), indicating higher mitochondrial density (Fig. 
6H). Gene expression of the oxidative muscle marker MhcI showed a 6.6-fold increase in Acsl1M-
/- white gastrocnemius, but not in red gastrocnemius or soleus (Fig. 6I). PGC1α activation 
increases mitochondria numbers and oxidative muscle fibers (131). Compared to controls, loss of 
ACSL1 increased Ppargc1α gene expression by 35% in glycolytic white gastrocnemius but 
decreased Ppargc1α gene expression in oxidative red gastrocnemius (Fig. 6J). PPARδ mediates 
the posttranscriptional increase of PGC-1α (132). The absence of an increase in mRNA 
expression in Acsl1M-/- mice suggests that lack of ACSL1 did not activate PPARδ (Supl. Fig. 
5D). Taken together, these data suggest that loss of ACSL1 promotes a compensatory increase in 





Deletion of Acsl1 impaired mitochondrial morphology but not OCR. To determine 
whether loss of ACSL1 alters mitochondrial function, we measured the OCR in isolated 
mitochondria with pyruvate and malate (complex I substrates) or succinate and rotenone 
(complex II substrate plus complex I inhibitor). We detected no difference under either basal or 
ADP- or FCCP- stimulated states, indicating that despite a 90% reduction of FAO, mitochondria 
from Acsl1M-/- muscle function normally under resting conditions (Fig. 7A,  B). However, 
because Acsl1M-/- mice are intolerant to endurance exercise (120), and had impaired voluntary 
running capacity and an exercise-induced increase in the percentage of central nuclei, we 
determined how exercise would affect mitochondrial function. Mice were allowed to run 
voluntarily on running wheels for one week before measuring the OCR in isolated mitochondria. 
Again, we detected no difference between genotypes (Fig. 7C, D). The amount of cardiolipin and 
its fatty acid composition regulate mitochondrial function and pathology (133).  In ACSL1-
deficient hearts, the major cardiolipin (CL) species tetralinoleoyl-cardiolipin is 83% lower than 
in control hearts (44). We set out to measure cardiolipin and other phospholipid species in 
muscles (Suppl. Figs.7, 8). In both gastrocnemius and soleus, minimal changes in the amount 
and fatty acid composition of cardiolipin were detected.  Lipidomics analysis showed alterations 
in some phospholipid species. Similar to the heart knockout, the content of soleus 
phosphatidylinositol (PI) (38:4) was 50% lower in Acsl1M-/- mice than controls.  In both ACSL1-
deficient gastrocnemius and soleus, compared to controls, the amounts of PC (34:1) and PC 
(36:1) were higher, and PC (38:6) was lower. These changes were different from what was 
observed in ACSL1-deficient heart suggesting that lack of ACSL1 changed phospholipid species 
in skeletal muscle, but the role of muscle ACSL1 differs from heart ACSL1. Although loss of 




consequently, the content of mitochondrial protein in whole gastrocnemius decreased (Fig. 7E), 
contrary to the results for mitochondrial biogenesis (Figs. 6). We reasoned that the already 
damaged mitochondria would be vulnerable to the mitochondrial isolation process including 
homogenization and centrifugation, which could cause selective exclusion of damaged 
mitochondria. Indeed, a study showed that mitochondria isolation preparation intends to obtain 
well coupled and intact mitochondria (134). Despite the increased mitochondrial numbers, the 
mitochondrial structure, morphology, and integrity from Acsl1M-/- gastrocnemius were unknown. 
If Acsl1M-/- muscle contained damaged mitochondria, the mitochondria isolation preparation 
would selectively eliminate them. Supporting this idea, mitochondria isolated from control and 
Acsl1M-/- gastrocnemius showed equivalent membrane integrity as assessed by measuring 
mitochondrial cytochrome c oxidase activity in the presence and absence of the detergent, n-
dodecyl β-D-maltoside (data not shown). To assess how loss of ACSL1 affects mitochondria 
morphology, electron microscopy was performed to visualize mitochondrial ultrastructure of 
resting mice fasted for 4 h (Fig. 7F). The presence of swollen mitochondria suggested that lack 
of ACSL1 damaged cristae structure in gastrocnemius. Although cristae disruptions were mostly 
absent in mitochondria from Acsl1M-/- soleus, large vacuoles were observed. Acsl1M-/- soleus had 
2.5 fold higher TAG than controls, and we speculate that these vacuoles could be mitochondria-
associated lipid droplets. In sum, our data indicated that although OCR from isolated 
mitochondria remained unchanged, lack of ACSL1, indeed, damaged mitochondrial structure in 
gastrocnemius.  
Deletion of Acsl1 increased protein turnover in glycolytic but not oxidative fibers. Loss 
of ACSL1 reduced palmitate oxidation, but glucose use in Acsl1M-/- and control muscle was 




oxidize more amino acids derived from muscle protein. In contrast to Cpt1M-/- mice (26), we 
detected no difference in the mRNA expression of genes related to peroxisomal FAO (Supl. Fig. 
5C), ruling out a compensatory increase in peroxisomal FAO, so we focused on protein turnover.  
Under resting conditions, deletion of Acsl1 did not change either the ratio of gastrocnemius to 
body weight or muscle cell size measured by cross sectional area, indicating that neither 
hypertrophy nor atrophy was present (Supl. Fig. 6A, B). We reasoned that an increased drain on 
amino acids for energy and the resulting repeated muscle damage, death, and regeneration would 
accelerate protein turnover in Acsl1M-/- mice. Indeed, high rates of protein turnover have been 
observed in several muscle diseases. In Mdx mice, gastrocnemius protein turnover is higher than 
in control mice (135,136). Higher protein turnover is also observed in severely affected patients 
with limb girdle muscular dystrophy (137).  To assess the rate of protein synthesis in Acsl1M-/- 
muscle, we performed the SUnSET assay. In this assay, puromycin, an aminoacyl-tRNA analog, 
is incorporated into newly synthesized protein and stops protein elongation. The amount of 
puromycin labelled peptides , which can be detected by western blot with anti-puromycin 
antibody, serves as an indicator of new protein synthesis (122). At rest, the rates of new protein 
synthesis in Acsl1M-/-   and control gastrocnemius and soleus were similar (Supl. Fig. 9A, B); thus, 
we examined mice after exercise.  The rate of protein synthesis increases immediately after 
resistance training and endurance training (138-140), and we previously reported that during 
treadmill running plasma glucose concentration in Acsl1M-/- mice decreases from 80 mg/dl at 
1000 meters to 40 mg/ml at 1500 meters. In order to activate muscle contraction but not cause 
hypoglycemia and exhaustion, mice were exercised on the treadmill for 45 minutes (500 meters) 
at 12 m/min.  Immediately afterwards, we injected puromycin to examine the rate of new protein 




gastrocnemius than in controls, but no difference was observed in red gastrocnemius or soleus, 
indicating that, similar to the presence of central nuclei and the expression of Myog and Myod, 
the increase in protein synthesis was more pronounced in glycolytic fibers (Fig. 8A, B). 
Collectively, these data suggest that under non-exercised conditions, the residual ACSL activity 
and FAO in Acsl1M-/- gastrocnemius were sufficient to maintain normal protein metabolism, but 
the defects in protein metabolism imposed by loss of ACSL1 become evident when energy 
demands increased during exercise. Thus, in glycolytic muscle from Acsl1M-/- mice, protein 
synthesis increased, suggesting a higher protein turnover rate.  
Discussion 
 
ACSL1-activated FA is specifically directed to mitochondrial β-oxidation in highly 
oxidative tissues(1). Mice lacking muscle ACSL1 have reduced capacity for endurance exercise 
and impaired metabolic homeostasis (120). What is less evident is the extent of and the mechanism 
that damages muscle in Acsl1M-/- mice. Our results indicate that compared to controls, mice lacking 
ACSL1 had impaired overall physical performance; deficiency of ACSL1 caused muscle damage, 
apoptosis, and regeneration, as well as promoting mitochondrial biogenesis and increased protein 
turnover predominantly in glycolytic muscle. Heart prefers FA as its major fuel, and lack of 
ACSL1 in heart activates the mTOR pathway, resulting in cardiac hypertrophy (3). Skeletal muscle 
also uses FA as its primary fuel both at rest and during sustained exercise. In contrast to the heart, 
no weight change was detected in the gastrocnemius, indicating that the deficiency of ACSL1 
caused neither hypertrophy nor atrophy in gastrocnemius; further, the mTOR pathway was not 
upregulated (data not shown), suggesting that ACSL1 deficiency had different outcomes in heart 
and skeletal muscle. Evidence suggests that enhanced glucose metabolism underlies mTORC1 




change in glucose uptake was detected in muscle deficient in ACSL1 (3). Furthermore, no 
difference was found in the rate of pyruvate oxidation between control and Acsl1M-/- mice when 
muscle homogenates were incubated with [2-14C]-pyruvate. When excess glucose was provided 
during a hyperinsulinemic-hyperglycemic clamp, Acsl1M-/- muscle took up less glucose than 
controls, and less glucose was required to maintain a consistent plasma glucose (225 mg/dl) 
concentration, supporting the notion that Acsl1M-/- mice are mildly insulin resistant. This 
interpretation is not consistent with our previous finding that, compared to controls, insulin 
stimulation results in enhanced Akt phosphorylation in Acsl1M-/- gastrocnemius. These opposite 
results suggest an insufficient translocation of GLUT4 to the sarcolemma membrane in muscle, 
despite the insulin-dependent activation of Akt. Indeed similar observations were reported in 
patients with a myopathy imposed by critical illness (142). Taken together, these data indicate that 
in Acsl1M-/- mice the reduction in mitochondrial FAO did not directly result in enhanced muscle 
glucose use.   
As an essential enzyme for fatty acid β-oxidation, lack of muscle CPT1b blocks 
mitochondrial FAO, which initiates an adaptive response in muscle, including mitochondrial 
biogenesis, compensatory peroxisomal FAO, and amino acid catabolism, as well as increased 
carbohydrate use (26). Similar to CPT1b, ACSL1 also plays an indispensable role in FAO in 
oxidative tissues. Lack of ACSL1 inhibited FAO by 90% in gastrocnemius and 72% in soleus. 
Although Acsl1M-/- mice developed severe hypoglycemia after endurance exercise, carbohydrate 
use was not changed in muscle (120).  Skeletal muscle is required to supply amino acids for hepatic 
gluconeogenesis and the maintenance of blood glucose levels during prolonged fasting (143). 
During both fasting and exercise, serum glucose levels are maintained by a muscle switch to FAO 




/- mice was not due to increased glucose uptake and use, we hypothesized that it resulted from 
insufficient delivery of gluconeogenic amino acids to the liver after both an overnight fast and 
endurance exercise (14). In support of this interpretation was the finding that when the 
gluconeogenic substrate glycerol was supplied after an overnight fast, glucose production by 
Acsl1M-/- mice was greater than in controls, indicating a higher liver gluconeogenic capacity (120).  
A likely cause for the inadequate muscle release of gluconeogenic substrates is the increased 
protein turnover and use of amino acids for energy within the muscle itself. Exercise activates 
muscle glycogenolysis, the TCA cycle, and amino acid uptake. The rate of muscle protein 
synthesis is immediately increased after mild resistance exercise in both human and rats (138), and 
endurance exercise such as running or cycling is also associated with an acute increase in  muscle 
protein synthesis.  To activate muscle contractions without causing exhaustion (120), we exercised 
mice on a treadmill for 45 minutes. Compared to controls, Acsl1M-/- glycolytic muscle showed 
increased protein synthesis, an effect that was not observed in oxidative muscles. Enhanced protein 
synthesis suggests an active protein metabolism which occurred exclusively in exercised glycolytic 
muscle. 
The imbalance in muscle protein metabolism not only prevented adequate release of 
substrate for hepatic gluconeogenesis, but also restricted muscle homeostasis, thereby resulting in 
a mild, but persistent myopathy in Acsl1M-/- mice. The marked increase of the number of central 
nuclei, particularly after exercise, suggested that muscle regeneration was robust in Acsl1M-/- 
gastrocnemius. Supporting this observation are data from Acsl1M-/- gastrocnemius demonstrating 
increased mRNA expression of the muscle regeneration markers Myod and Myog and the positive 
staining of the mitosis marker phospho-histone H3. The absence of necrosis made us think 




caspase-3 plays a master role in the induction of both the intrinsic and extrinsic apoptosis pathways 
(129). The expression of full-length caspase-3 only in Acsl1M-/- muscle suggested that apoptosis 
was a likely cause of Acsl1M-/- muscle cell death. Skeletal muscle contains stem cells, satellite cells. 
After muscle damage, inflammatory cells migrate to the injured locus and remove debris. Then the 
normally quiescent satellite cells proliferate and differentiate to form mature myoblasts, which 
fuse with each other and with surviving fibers to repair muscle cells (144,145). Positive 
immunostaining of cleaved caspase-3, as well as evidence of macrophage infiltration supports the 
idea that apoptosis underlies muscle cell death in Acsl1M-/- gastrocnemius. Although lack of 
ACSL1 inhibits 90% of FAO, we observed a 6-fold increase of mRNA expression of MhcI, a 
marker of oxidative muscle fibers, in white gastrocnemius. Furthermore, coordinate changes 
including upregulation of genes related to mitochondrial FAO, increased mitochondrial copy 
number, and more oxidative muscle fibers evidenced by SDH staining suggest that Acsl1M-/- muscle 
responded to reduced FAO by increasing mitochondrial biogenesis and enabling a fiber type switch 
from glycolytic to oxidative. Similar changes are also observed in mice lacking very long chain 
acyl-CoA dehydrogenase (VLCAD-/-), which catalyzes the first of four sequential reactions in the 
mitochondrial β-oxidation of long-chain fatty acids (68). In 3 month old VLCAD-/- mice, mRNA 
expression of the oxidative muscle marker, troponin I, is upregulated (146). Despite increased 
mitochondrial numbers, we found no difference in mitochondrial OCR measured by Seahorse 
Bioanalyzer. The mitochondria isolation procedure may have selectively excluded damaged 
mitochondria from Acsl1M-/- muscle. The likelihood of exclusion is supported by the 18% less of 
mitochondrial protein content from Acsl1M-/- compared to control gastrocnemius. However, the 
presence of abnormal swollen mitochondria in Acsl1M-/- gastrocnemius indicated that ACSL1 was 




  Compared to controls, Acsl3 mRNA expression increased 3.4-fold in Acsl1M-/- soleus; 
increased Acsl3 mRNA was also observed in heart that lacked ACSL1 (5). The specific function 
of ACSL3 has not been determined, but it is implicated in the synthesis of PC (147) and in the 
KRAS-mediated production of acyl-CoAs directed towards β-oxidation in lung cancer cells  (148).  
In addition to the defects observed in glycolytic muscle lacking ACSL1, oxidative muscle, 
particularly soleus, appeared to be protected. Compared to controls, the ratio of soleus weight to 
total body weight was significantly higher, and cell sizes assessed by cross section areas, were 
larger (Supl. Fig. 6 B, D). Compared to gastrocnemius, fewer soleus cells contained central nuclei, 
and unlike gastrocnemius, the number of central nuclei increased only minimally after exercise.  
Further, changes in expression of muscle regeneration markers were not observed in soleus, and 
we did not observe evidence for enhanced mitochondrial biogenesis or increased protein turnover 
in soleus. Similar muscle-specific differences have been observed in several types of muscle 
diseases with different levels of metabolic alterations. For example, in Spinal and bulbar muscular 
atrophy (SBMA) knockout mice and muscular dystrophy patients and mice, glycolytic muscle are 
more severely affected, and metabolic changes are characterized by a glycolytic-to-oxidative fiber-
type switch (149-151). Whereas gastrocnemius consists of mixed oxidative and glycolytic fiber, 
soleus is composed of primarily oxidative fibers. The mRNA expression of genes linked to FA 
transport and TAG synthesis are higher in soleus than in a predominantly glycolytic muscle (EDL), 
suggesting that soleus has a higher capacity for lipid accumulation (152). Despite its 90% lower 
ACSL activity, compared to controls, ACSL1-deficient soleus contained 2.5 times more TAG.  
Accumulation of excess fatty acids in TAG pools diverts molecules from potentially lipotoxic 
pathways, which may explain why less damage was observed in Acsl1M/- soleus (153). Indeed 




often adjacent to mitochondria along myofibrils. Those lipid droplets serve metabolic fuel during 
exercise or fasting (152,154). Taken as a whole, our data indicate that lack of ACSL1-dependent 
fatty acid metabolism is more problematic in glycolytic than oxidative muscle.  
 Although we discovered that, compared to controls, the rate of protein synthesis was higher 
in ACSL1-deficient glycolytic muscle, suggesting that increased protein turnover occurred in 
Acsl1M-/- mice, what remains lacking is a measure of the rate of protein degradation. The rates of 
protein synthesis and protein degradation define protein turnover. If the rate of protein degradation 
exceeds protein synthesis, atrophy would develop.  Conversely, hypertrophy would result from 
synthesis in excess of degradation. However, because neither atrophy not hypertrophy developed 
in Acsl1M-/- gastrocnemius, the rates of protein synthesis and degradation must have been 
equivalent. Confirmation of increased protein degradation could be performed measuring 









Figure. 2.1. Lack of Acsl1 reduced muscle ACSL activity and FAO.  A, Homogenates of 
skeletal muscle, heart, and gonadal white adipose tissue (GWAT) were subjected to western blot 
and immunoprobed with ACSL1 and GAPDH antibodies. B, mRNA expression of Acsl isoforms 
in soleus. Data were normalized to mRNA expression of 18S, n=3 per genotype. C, ACSL specific 
activity of total membrane preparations from white gastrocnemius (WGastroc), red gastrocnemius 
(RGastroc), and soleus, n=4 per genotype. D, Palmitate oxidation in muscle homogenates from 
white gastrocnemius red gastrocnemius, and soleus. C: control. KO: Acsl1M-/-, n=4 per genotype.  





Figure. 2.2. Lack of Acsl1 increased muscle glycogen content, but glucose use was unchanged. 
A, TAG content of white gastrocnemius (WGastroc), red gastrocnemius (RGastroc), and soleus, 
n=3-4 per genotype. B, Glycogen content of white gastrocnemius, red gastrocnemius, and soleus 
in unfasted mice, n=6-9 per genotype. C, [1-14C]2-deoxyglucose uptake in gastrocnemius in mice 
exposed to 4°C for 2 h, n=3 per genotype.  D, [2-14C] Pyruvate oxidation in white and red 
gastrocnemius homogenates, n=5-6 per genotype. E-H, Hyperglycemic-hyperinsulinemic clamp, 
n=9 per genotype; E, Glucose was clamped at 225 mg/dl. F, Whole body glucose uptake. G, 
glucose infusion rate. H, Area under curve of glucose infusion rate. Data are presented as means 







Figure. 2.3. Running capacity was impaired in Acsl1M-/- mice.  A-E, Mice were individually 
housed with access to a running wheel for 2 weeks in a room with 12h light/dark cycle, n=7 per 
genotype. A, Cumulative distance run. B, Daily average running speed during the dark period. C, 
Daily maximal running speed during the dark period. D, Approximate time, during which mice 
did not run, was recorded during the dark cycle.  E, Sum of each day’s break time during the dark 
period. F, Grip strength scores for wire hang grip test, n=9-12 per genotype. Data are presented as 












Figure. 2.4. Evidence of myopathy in Acsl1M-/- mice. Mice were fasted for 4 h. Plasma CK (A) 
and AST (B) activities, n=11-14 per genotype. C-D, Approximately 2000 cells (total) from 4 
randomly selected areas in two adjacent gastrocnemius sections and all cells from an entire soleus 
section were counted.  Percent of cells containing central nuclei in gastrocnemius and soleus from 
non-exercised (No Ex) mice and exercised (Ex) mice after 2 weeks of voluntary running, n=4 per 
genotype. E-F, Representative 100 µm images of H&E staining of gastrocnemius and soleus. G, 
mRNA expression of muscle regeneration markers Myog and Myod in white gastrocnemius 
(WGastroc), red gastrocnemius (RGastroc), and soleus. Data were normalized to mRNA 







Figure. 2.5. Deletion of Acsl1 resulted in skeletal muscle cell apoptosis. A, Mice were fasted 
for 4 h. Muscle homogenates were subjected to western blot analysis and immunoprobed with anti-
caspase-3 and anti-GAPDH. B, Tissue was fixed in 10% formalin and immunostained with anti-
cleaved caspase-3. Representative 50 µm images of immunostained apoptosis marker, cleaved 
caspase-3 in gastrocnemius. C, Tissue was immunostained with anti-F4/80, a macrophage cell 












Figure. 2.6. Deletion of Acsl1 promoted compensatory mitochondrial biogenesis in glycolytic 
fibers. A, ACSL activity in total membrane fractions measured with palmitate, stearate, linoleate, 
or oleate, n =3 per genotype. B, ACSL activity in muscle homogenates and mitochondrial fractions 
measured with 50 µM palmitate, n=3-4 per genotype. C, Gastrocnemius total homogenate, cytosol, 
and mitochondria were subjected to western blot and immunoprobed with anti-ACSL1, anti-
VDAC, and anti-GAPDH. D, mitochondrial copy number in white gastrocnemius (WGastroc), red 
gastrocnemius (RGastroc), and soleus. Data was normalized to genomic DNA H19, n=4-5 per 
genotype. E-F, mRNA expression of FAO genes in gastrocnemius (n=4-5 per genotype) and soleus 
(n=5-7 per genotype). Data were normalized to mRNA expression of 18S.  G, Representative 
image of gastrocnemius succinate dehydrogenase staining. H, Percent of oxidative muscle fibers, 
n=6 per genotype. I, mRNA expression of MhcI in white gastrocnemius, red gastrocnemius, and 
soleus. Data were normalized to mRNA expression of 18S, n=3-7 per genotype.  J, Ppargc1 
mRNA expression in white and red gastrocnemius. Data were normalized to mRNA expression of 

















Figure. 2.7. Deletion of Acsl1 impaired mitochondrial morphology. A-B, Mice were fasted for 
3 h, then oxygen consumption rate (OCR) was measured in isolated gastrocnemius mitochondria 
using malate and pyruvate (n=3 per genotype) or succinate (n=6 per genotype) as substrates. C-D, 
Mice had access to a voluntary running wheel for 1 week. On the day of the study, mice were 
fasted for 3 h. OCR was measured in isolated mitochondria with malate and pyruvate or succinate 
as substrates, n=5-8 per genotype. E, mitochondria protein content from gastrocnemius per 
individual mouse, n= 14 per genotype. F, Representative electron microscopy images.  Acsl1M-/- 
gastrocnemius shows abnormal cristae.  Acsl1M-/- soleus shows mitochondria-associated lipid 









Figure. 2.8. Deletion of Acsl1 enhanced protein turnover in glycolytic muscle after endurance 
exercise. Mice were exercised on a treadmill for 45 min, then puromycin was injected IP. Thirty 
min later, white gastrocnemius (WGastroc), red gastrocnemius (RGastroc), and soleus were 
collected and homogenized. Homogenates were subjected to western blot and immunoprobed with 
anti-puromycin and anti-ACSL1. Membranes were stained with Ponceau S. Image J software was 
used to perform densitometry quantification. A, Representative western blots of anti-puromycin 
and anti-ACSL1, and membranes stained with Ponceau S. B, Quantifications of the puromycin 
incorporation. Data were normalized by Ponceau S, n=4-5 per genotype.  Data are presented as 





Supplemental Figure. 2.1. Deletion of Acsl1 promoted lipid droplet accumulation in soleus. 
Muscles were snap frozen in liquid nitrogen-cooled isopentane. Oil red O (ORO)-stained section 
and adjacent succinate dehydrogenase staining (SDH)-stained section.  Representative 100 µm 









Supplemental Figure. 2.2. TCA flux gene expression did not change in gastrocnemius. mRNA 
expression of Pdha1 and Cs in gastrocnemius. Data were normalized to mRNA expression of 18S, 
n=4-5 per genotype. Data are presented as means ± SEM.  
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Supplemental Figure. 2.3. Voluntary running average speed, maximal speed, and periods of 
non-running time during the light cycle. A, Daily average running speed during the light cycle, 
n=7 per genotype. B, Daily maximal running speed during the light cycle, n=7 per genotype. D, 
Approximate time during the light cycle in which mice did not run, n=7 per genotype. Data are 







Supplemental Figure. 2.4. Deletion of Acsl1 promoted muscle regeneration in gastrocnemius. 
Tissue was fixed in 10% formalin and immunostained with anti-phosphor-Histone H3. 
Representative 100 µm images of immunostained mitosis marker, phospho-histone H3 in 






Supplemental Figure. 2.5. Gene expression of inflammatory markers, peroxisomal FAO 
genes, and PPARδ were unchanged in Acsl1M-/- muscle. A-B, mRNA expression of 
inflammatory marker genes including Il1, Il6, and Tnfα in white gastrocnemius (WGastroc, n=8-
9, per genotype) and red gastrocnemius (RGastroc, n=4-5 per genotype).  Data were normalized 
to mRNA expression of 18S.  C, mRNA expression of peroxisomal FAO genes. Data were 
normalized to mRNA expression of 18S,   n=4-5 per genotype. D, mRNA expression of Pparδ in 
white gastrocnemius (n=8-10 per genotype) and red gastrocnemius (n=5 per genotype). Data were 






Supplemental Figure. 2.6. Deletion of Acsl1 increased soleus weight but not gastrocnemius.  
A-B, Mice were fasted for 4 h. Wet weights of gastrocnemius and soleus were measured. A, Ratio 
of gastrocnemius weight to body weight, n=6-12 per genotype. B, Ratio of soleus weight to body 
weight, n=8 -12 per genotype. C-D, Sections from gastrocnemius and soleus muscle were stained 
with H&E. Slides were digitally scanned and the cross section areas were measured by Aperio 
Scanscope Software. C, Cross section area of gastrocnemius, n=3-4 per genotype. D, Cross section 





Supplemental Figure. 2.7. Phospholipid species from gastrocnemius.  Mice were fasted for 4 
hours. Gastrocnemius was collected and immediately snap frozen.  Total lipid was extracted and 
subjected to LC/MS to analyze phospholipid species. Data are presented as relative amounts 
normalized by internal standards, n=6 per genotype. A-B, Individual and total PC species.  C, 
Individual cardiolipin species. D-E, Individual and total PE species. F-G, Individual and total PI 






Supplemental Figure. 2.8. Phospholipid species from soleus..  Mice were fasted for 4 hours. 
Soleus was collected and immediately snap frozen.  Total lipid was extracted and subjected to 
LC/MS to analyze phospholipid species. Data are presented as relative amounts normalized by 
internal standards, n=6 per genotype. A-B, Individual and total PC species.  C, Individual 
cardiolipin species. D-E, Individual and total PE species. F-G, Individual and total PI species. Data 









Supplemental Figure. 2.9. Deletion of Acsl1 did not change protein turnover when mice were 
at rest.  A, Mice were fasted for 4 hours. Puromycin was injected IP, Thirty min later, white 
gastrocnemius (WGastroc), red gastrocnemius (RGastroc), and soleus were collected and 
homogenized. Homogenates were subjected to western blot and immunoprobed with anti-
puromycin and anti-ACSL1. Membranes were stained with Ponceau S. Image J software was used 
to perform densitometry quantification. A, Representative western blots of anti-puromycin and 
anti-ACSL1, and membranes stained with Ponceau S.  B, Quantifications of the puromycin 
incorporation. Data were normalized by Ponceau S. n=5-6 per genotype.  Data are presented as 





Supplemental Table 1. Primer sequences. 
Gene Forward Reverse 
mtDNA CCTATCACCCTTGCCATCAT GAGGCTGTTGCTTGTGTGAC 
H19 GTACCCACCTGTCGTCC GTCCACGAGACCAATGACTG 
18S TTCTGGCCAACGGTCTAGACAAC CCAGTGGTCTTGGTGTGCTGA 
MhcI CCTTGGCACCAATGTCCCGGCTC GAAGCGCAATGCAGAGTCGGTG 
Hadha  TGACGCTGGTTATCTTGCTG ATCAGGGCCTTCGATTCTTT 
Ech1 TCGCTACTGCACTCAGGATG AGCAGCCAAGCCCATATCTA 
Cpt2 TGCCCAGGCTGCCTATCCCTAAACT GCTCCTTCCCAATGCCGTTCTCAAAAT 
Cact CCAACGCTGCCTGTTTCCTTGG GCCAAGCCTGGAGCTCTGATCAC 
Crat ATGAGCATGCAGCTGCAGAA GCGTAAGAGGTGTCCATGAAGA 
Pdha1 GGTTGCTTCCCGTAATTTTG GTGAGCACTGTGGTGACTGG 
Cs CGGGAGGGCAGCAGTATCGG ACCACCCTCATGGTCACTATGGATG 
Pgc1α AGCCTCTTTGCCCAGATCTTC CCATCTGTCAGTGCATCAAATGA 
Acox1 CTTCGAGGGGGAGAACACT CCCGACTGAACCTGGTCATA 
Peci GGGGATAGAGGAGGCAGCTA AACCAGAGGCTTGGGAAAGT 
Decr2 CGGATCGCAGAGATTTTCAT CTTAGCAGCCGTGGTCACTT 
Pmp70 TGGAGCAGAAGTACGAAGGAG TCTCCCGTTTATTCCCATTG 
Pex19 TGTACCCATCCCTGAAGGAG GAGGAGTGGAGTCCTGGTGA 
Crot  AGTGCTCGAACGAACCTGTTG GCCTTTGCCCACCGAGTT 
MyoD CGCTCCAACTGCTCTGATGGCA TGCTGCTGCAGTCGATCTCTCA 
MyoG CAACCAGGAGGAGCGCGATCTCCG AGGCGCTGTGGGAGTTGCATTCACT 
Acsl1 TGGGGTGGAAATCATCAGCC CACAGCATTACACACTGTACAACGG 
Acsl3 CAATTACAGAAGTGTGGGACT CACCTTCCTCCCAGTTCTTT 
Acsl4 TGCCAAAAGTGACCAGTCCTATG TGTTACCAAACCAGTCTCGGGG 
Acsl5 TCCCAGCCCACCTCTGATGATGTG ACAAACTGTCCCGCCGAATG 











Rationale for Chapter 3 
FATP1 is expressed in macrophages and deletion of Fatp1 metabolically programs 
macrophage to a pro-inflammatory M1 phenotype (18). Hence, we hypothesized that mutated 
fatty acid metabolism due to the deletion of Fatp1 would promote atherogenesis. Due to their 
inexpensive cost and short time frame of atherosclerosis development, the LDL receptor 
knockout mouse (Ldlr-/-) has been extensively used in atherosclerosis research (155). When Ldlr-
/-
 mice are exposed to a Western Diet (21% fat and 0.2% cholesterol), they develop advanced 
lesions in the aortic sinus after 3 months and in the innominate artery after 6 to 9 months (156).  
Transplantation of bone marrow cells into Ldlr-/- mice allows to study specific roles of the newly 
transplanted hematopoietic cells. Deletion of Fatp1 polarizes macrophage to a pro-inflammatory 
phenotype. Bone marrow collected from Fatp1+/+ mice or Fatp1-/- mice were transplanted into 
Ldlr-/- mice to study the effect and the mechanism of FATP1-mediated macrophage fuel 
metabolism in atherogenesis. The data showed that lack of macrophage FATP1 increases the 
lesion size in Ldlr-/- aortic sinus and aorta, which is at least partially caused by increased lesion 




CHAPTER 3: LACK OF MYELOID FATP1 INCREASES ATHEROSCLEROTIC 
LESION SIZE IN Ldlr-/- MICE2 
Summary 
 
Altered metabolism is an important regulator of macrophage (MΦ) phenotype, which 
contributes to inflammatory diseases such as atherosclerosis. Broadly, pro-inflammatory, 
classically-activated MΦs (CAM) are glycolytic while alternatively-activated MΦs (AAM) 
oxidize fatty acids although overlap exists. We previously demonstrated that MΦ fatty acid 
transport protein 1 (FATP1, Slc27a1) was necessary to maintain the oxidative and anti-
inflammatory AAM phenotype in vivo in a model of diet-induced obesity. The aim of this study 
was to examine how MΦ metabolic reprogramming through FATP1 ablation affected the process 
of atherogenesis. We hypothesized that FATP1 limits MΦ-mediated inflammation during 
atherogenesis. Thus, mice lacking MΦ Fatp1 would display elevated formation of atherosclerotic 
lesions in a mouse model lacking the low-density lipoprotein (LDL) receptor (Ldlr-/-). We 
transplanted bone marrow collected from Fatp1+/+ or Fatp1-/- mice into Ldlr-/- mice and fed 
chimeric mice a Western diet for 12 weeks. Body weight, blood glucose, and plasma lipids were 
measured. Aortic sinus and aorta lesions were quantified. Atherosclerotic plaque composition, 
oxidative stress, and inflammation were analyzed histologically. 
                                                            
2This chapter previously appeared as an article in the journal Atherosclerosis. The original citation is as follows: 





Compared to Fatp1+/+Ldlr-/- mice,  Fatp1-/-Ldlr-/- mice exhibited significantly larger 
lesion area  and elevated oxidative stress  and inflammation in the atherosclerotic plaque. 
Macrophage and smooth muscle cell content did not differ by Fatp1 genotype. There were no 
significant systemic alterations in LDL, HDL, total cholesterol, or triacylglyceride, suggesting 
that the effect was local to the cells of the vessel microenvironment in a Fatp1-dependent 




Macrophages (MΦs) play a central role in the pathogenesis of atherosclerosis through 
clearance of modified LDL particles, efferocytosis, and control of the immune milieu (158-160). 
MΦs are a diverse population of cells based on site of origin, location, surface markers, 
functional analysis, and metabolic phenotype (161,162). While most work has focused on the 
former characteristics, little work has been conducted on understanding the metabolic phenotype 
of MΦs, or how MΦ metabolic phenotype influences disease progression, until recent years 
(97,163). In general, in vitro studies have shown that pro-inflammatory classically activated 
MΦs (LPS and IFN- stimulated, CAM or M1-like) are highly glycolytic while 
immunoregulatory alternatively activated MΦs (IL4-stimulated, AAM or M2-like) primarily 
oxidize fatty acids (18,107). However, in vivo MΦ phenotype is highly dynamic, with mixed 
inflammatory and metabolic phenotypes (90,91,97,101,113).  Previous reports from our lab and 
others have provided evidence that when substrate metabolism is modulated, a macrophage’s 
response to specific stimuli is dramatically altered. Fatty acid transport protein 1 (FATP1, 
Slc27a1) is an acyl-coA synthetase wherein expression within hematopoietic populations is 
limited to MΦs and plasmacytoid dendritic cells (164), but not other cells that may contribute to 
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inflammation in atherosclerosis including monocytes, microglia, B cells, T cells, neutrophils and 
eosinophils (18) . We have recently reported through loss and gain of function models that 
FATP1 is necessary to maintain the immunoregulatory AAM phenotype in vivo and ex vivo. 
Fatp1 is downregulated with pro-inflammatory stimulation of bone marrow derived MΦs (18). 
Chimeric mice lacking Fatp1 through bone marrow transplantation and fed high fat diet gained 
more weight and had impaired glucose tolerance on high fat diet, along with greater white 
adipose mass, MΦ infiltration, and crown like structures formation. Consequently, in white 
adipose tissue of Fatp1-/- transplanted mice, inflammation was elevated with evidence of 
oxidative stress. Fatp1-/- adipose tissue MΦs (ATMs) isolated from white adipose were more 
CAM-like compared to ATMs isolated from Fatp1+/+ transplanted mice fed a high fat diet (18). 
In vitro studies additionally demonstrated that MΦs lacking Fatp1 displayed a hyper-
inflammatory response to CAM stimuli, with elevations in iNOS (Nos2), among others, and 
reductions in immunoregulatory AAM marker arginase 1 (Arg1). Furthermore, absence of Fatp1 
led to a metabolic shift from fatty acid uptake and oxidative metabolism to increased glucose 
transporter GLUT1 expression, glycolysis, and metabolic intermediates associated with oxidative 
stress and pentose phosphate pathway (18). Conversely, an in vitro gain of function model was 
utilized by over-expressing Fatp1 in the RAW264.7 CAM-like MΦ cell line. RAW MΦs over-
expressing Fatp1 failed to be CAM activated, displayed blunted GLUT1 expression and reduced 
glucose metabolism, and exhibited increased fatty acid uptake and metabolism (18). Thus, Fatp1 
can not only direct the metabolic flexibility of MΦs but the inflammatory phenotype in vitro and 
in high fat diet-exposed mice, which begs the question of the role of MΦ Fatp1 in other 
metabolic diseases.  
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Cardiovascular diseases such as atherosclerosis are the cause of approximately 1 in 3 
deaths within the United States and are the leading cause of death worldwide (165). MΦ-
mediated inflammation is a critical component of atherosclerotic plaque formation with MΦ 
glycolysis associated with poorer outcomes (114). Atherosclerosis is an ongoing inflammatory 
process, during which MΦs mediate all stages of the disease from initiation through progression 
and, ultimately, thrombotic complications, as well as resolution (158). Our previous work 
indicated that there is a critical link between fatty acid transport/metabolism and inflammation in 
atherosclerosis, demonstrating the need to further understand novel regulators of MΦ substrate 
metabolism (166-169). Because MΦ lipid metabolism plays a central role in the pathogenesis of 
atherosclerosis, we hypothesized that MΦs with demonstrated blunted fatty acid metabolism and 
elevated glycolysis due to lack of Fatp1 would display increased atherogenesis. Herein, we 
report that while lack of hematopoietic Fatp1 led to no systemic alterations in lipids, Fatp1-/-
Ldlr-/- mice displayed greater plaque formation with evidence of oxidative stress and 
inflammation compared to Fatp1+/+Ldlr-/- mice. 
Methods 
 
Animals and Maintenance: Animal studies were performed with approval and in 
accordance with the guidelines of the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. Mice were housed in a climate controlled animal 
facility and ad libitium access to food and water. Fatp1-/- mice (81) were provided by Dr. 
Andreas Stahl (University of California, Berkeley). Fatp1 total body knockout (Fatp1-/-) and 
Fatp1 wild type (Fatp1+/+) bone marrow donor mice were generated using Fatp1-/+ breeding 
pairs to generate littermate controls. Ldlr-/- mice (stock number. 002207, Jackson Labs) were 
obtained at 4 weeks of age. At 6 weeks of age, bone marrow transplant was performed, (BMT, 
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below). Chimeric Ldlr-/- mice were then housed in a sterilized environment. Mice were 
maintained on chow diet for four weeks before challenge with Western Diet (Harlan Teklad, 
TD88137) for 12 weeks.  
Bone Marrow Transplantation: Upon arrival, N=34 4-week-old male Ldlr-/- mice were 
randomized to two experimental groups. At 6 weeks of age, recipient Ldlr-/- mice were 
administered two doses of X-ray irradiation (500cGy x 2, spaced 4 hours apart; X-RAD, North 
Branford, CT) as in previous work (18). Simultaneously, bone marrow was harvested from 6-8 
week old male Fatp1-/- and Fatp1+/+ donor mice. The femur and tibia were collected and bone 
marrow cells were flushed by ice-cold PBS, then centrifuged at 1,200 RPM at 4C for 5 minutes. 
Cell pellets were resuspended in HBSS buffer. Each recipient mouse received approximately 
5x106 bone marrow cells through retro-orbital injection under anesthesia in 100µl. Control 
animals were transplanted with the HBSS buffer only and died within 10 days of lethal 
irradiation.  
Body weight and composition: Body weight was measured prior to starting mice on diet 
and weekly until sacrifice. Body composition was measured at 6, 10, 13, 16, 19 and 22 weeks of 
age using the EchoMRI-100 quantitative magnetic resonance whole body composition analyzer 
(Echo Medical Systems, Houston, TX). Fat mass is presented as percent fat mass over total body 
weight (170).  
Lipids and glucose measurement: After 6 hours of fasting, blood was collected. Total 
cholesterol, LDL-cholesterol, HDL-cholesterol, and triacylglyceride were measured in the UNC 
Animal Clinical Chemistry and Gene Expression Core Facility by Vt350 Automated Chemical 
Analyzer from Ortho-Clinical Diagnostics Company (Rochester, NY). Mice were fasted for 6 
hours before blood glucose was measured and GTT was conducted. Blood glucose was measured 
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using a FreeStyle Freedom Lite glucometer (Abbot Diabetes Care, Inc., Alameda, CA). 
Intraperitoneal GTT was performed after 7 weeks on diet at 16 weeks of age. Briefly, 2.0gm/kg 
body weight of glucose was injected intraperitoneally and blood glucose was measured over 120 
minutes (18).  
Histology and quantification: Hearts were either transferred from 10% formalin to 70% 
ethanol stored at 4C for creation of formalin fixed paraffin embedded (FFPE) sections or 
transferred to 30% sterile sucrose for 72 hours for cyrosectioning. Serial interrupted sections 
from FFPE hearts and frozen hearts were either cut at 5µm or 10µm thickness. FFPE sections 
were stained with Masson’s trichrome for quantification of collagen content, necrotic core areas, 
and subendothelium cell numbers, MOMA2 (macrophage/monocyte monoclonal antibody) for 
MΦs, anti α-SMA (alpha-smooth muscle actin) for smooth muscle cells (SMC), anti 4HNE (4-
hydroxynonenal) for oxidative stress, and anti-IL6 (interleukin 6) for inflammation. The 
antibodies used for immunostaining were: MOMA2 (BioRad, MCA519G), anti α-SMA (Sigma, 
A5228), anti 4HNE (Abcam, ab48506), and anti IL6 (Novusbio, NB600-1131), which were 
respectively diluted as: MOMA2 (1:25), anti α-SMA (1:200), anti 4HNE (1:400), anti IL6 
(1:400). The secondary antibodies were reacted with peroxidase substrate (Vectorlabs, SK-
4605). Finally, slides were counterstained with methyl green. A color deconvolution algorithm, 
developed in collaboration with the UNC Translational Pathology Laboratory, was used to 
separate collagen for digital quantification (Definiens software). Quantification of collagen was 
calculated as optical density (OD) x percent of total positive area stained with collagen. Necrotic 
core areas and subendothelial cell numbers were normalized to the total quantified areas using 
Aperio ePathology software (Aperio, Buffalo Grove, IL) (170-172). Quantification of MΦ, SMC, 
oxidative stress, and inflammation were calculated as OD x percent of total positive area stained 
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with MOMA2, anti α-SMA, anti 4HNE, and anti IL6 similar to previous work (170). Frozen 
sections were stained with Oil red O to stain neutral lipids and hematoxylin counterstain for 
quantification of lesion area. Quantification of atherosclerotic lesions was performed as 
described (173). Serial interrupted sections were cut through the aorta at the origins of the aortic 
valve leaflets, and every other section (10 µm) throughout the aortic sinus (1600 µm) was stained 
with Oil Red O. Aortic lesion size from each section was measured by Aperio ImageScope 
software. Total aortic lesion size of each animal was obtained by the summation of 5 sections 
from the same mouse.  
Cell culture: Mouse thioglycollate-elicited peritoneal MΦs were obtained as described 
(169). Using carboxylate microspheres, phagocytic capacity  was measured ex vivo (174). 
Briefly, thioglycollate-elicited peritoneal MΦs were seeded on collagen coated Nunc Lab-Tek 
Chamber Slide (Sigma Aldrich, St. Louis, MO) overnight. Next day, carboxylated microspheres 
were incubated with MΦs for either 20 minutes or 60 minutes at 37°C. Goat anti-Mouse 
Rhodamine red-X (Life Technologies, CA) was first incubated with cells for 15 minutes. Cells 
were then permeabilized. Goat anti-Mouse Cy5 and Alexa 488-Phalloidin (Life Technologies, 
CA) were then incubated with cells for another 30 minutes. Cells were then mounted with 
Fluorescent mounting media. A ZEISS LSM 700 confocal microscope was used to capture the 
images (UNC Microscopy Core). Phagocytosis Index (PI) was calculated by numbers of 
microspheres adherent to or engulfed by cells, respectively, divided by total nuclei in the field 
and reported as beads/cell. Experiments were repeated 3 times, with 4 technical replicates per 
genotype per experiment, and 2 fields/well from each experiment were captured for analysis. 
Statistics: Statistical differences between experimental groups were determined by unpaired 
Student’s t-tests using statistical software within GraphPad Prism (GraphPad Software, Inc., La 
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Jolla, CA). All data are shown as mean ± standard error of the mean (SEM). p values less than 
0.05 were considered statistically significant.   
Results 
  
Fatp1+/+ Ldlr−/−and Fatp1-/-Ldlr−/− chimeric mice gained weight and adiposity at same 
rates. To study the effect of Fatp1 on mediating MΦ’s contribution to atherogenesis, chimeric 
models were created by bone marrow transplantation (Study design outlined in Supplemental 
Figure 1A). Six-week-old Ldlr-/- irradiated mice were transplanted with either HBSS or bone 
marrow collected from Fatp1+/+ or Fatp1-/- mice. Control mice transplanted with just HBSS died 
within 10 days (data not shown). After rescue from marrow transplant, Fatp1+/+ Ldlr−/−and 
Fatp1-/-Ldlr−/−mice were placed on Western Diet at 9 weeks of age and were maintained on diet 
until sacrifice at 22 weeks of age. There were no differences in weight gain or body composition 
between genotypes (Supplemental Figure 1B-C).   
Lack of Fatp1 led to increased atherogenesis in Fatp1-/-Ldlr−/−mice compared to 
Fatp1+/+Ldlr−/−mice. After 12 weeks on Western Diet, mice were sacrificed and aortas were 
isolated and stained with Oil Red O for lesion quantification (Figure 1 A). En face analysis 
indicated that Fatp1-/-Ldlr−/−mice displayed significantly greater (1.77-fold) plaque area 
compared to Fatp1+/+Ldlr−/−mice (Figure 1 B, p=0.001). Aortic root analysis was also conducted 
on sections stained with Oil Red O to determine lesion size. Aortic sinus lesion area was 
significantly increased by 1.72-fold in Fatp1-/-Ldlr−/−mice compared to Fatp1+/+Ldlr−/−mice 
(Figure 2 A-B, p=0.015). Deletion of Fatp1 did not change the percent necrotic area in aortic 
sinus.  (Figure 2 C-D).  Collagen positive area in aortic sinus was digitally quantified (Figure 
2E) and total nuclei within the subendothelium plaque area were counted (Figure 2F); there 
were no Fatp1-mediated significant differences detected in either parameter. 
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There were no systemic alterations in plasma lipids or glucose tolerance in Fatp1-/-
Ldlr−/−mice compared to Fatp1+/+Ldlr−/−mice. Because significant Fatp1-dependent differences 
were evident in atherogenesis, we next examined plasma lipid levels, to exclude potential 
systemic metabolic effects resultant from hematopoietic Fatp1 deletion. Figure 3 demonstrates 
that there were no differences in total plasma cholesterol, LDL cholesterol, HDL cholesterol or 
triacylglyceride in Fatp1-/-Ldlr−/−mice compared to Fatp1+/+Ldlr−/−mice (Figure 3 A-D). No 
differences in fasting blood glucose concentrations were detected from 10 to 22 weeks of age 
(Supplemental Figure 2A). Likewise, a GTT was conducted at 16 weeks of age after 7 weeks 
on diet, which indicated that there was no genotype effect on glucose tolerance (Supplemental 
Figure 2B). 
Deletion of Fatp1 did not alter plaque composition but increased oxidative stress 
and inflammation in atherosclerotic plaque. To further investigate potential mechanisms 
leading to increased lesion size, we analyzed atherosclerotic plaque cell composition and 
evidence of damage from oxidative stress and inflammation. IHC analysis showed that lack of 
Fatp1 did not change MΦ and SMC content within the plaque as assessed by MOMA2 and 
αSMA staining (Figure 4 A-D). Evidence of oxidative stress was measured by 4HNE staining, 
which showed a significant 1.63-fold increase in Fatp1-/-Ldlr−/−mice compared to 
Fatp1+/+Ldlr−/−mice (Figure 4 E-F, p=0.013). To investigate if lacking Fatp1 lead to increased 
plaque inflammation, IHC staining against IL-6 was performed. A 1.5-fold increase of IL6 
staining in Fatp1-/-Ldlr−/−mice was detected compared to Fatp1+/+Ldlr−/−mice (Figure 4 G-H, 
p=0.014). 
Fatp1 does not alter phagocytic capacity. Local MΦ function in the lesion 
microenvironment may also have contributed to the exacerbated atherogenesis in the absence of 
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Fatp1. MΦs bind and phagocytize oxidized LDL particles in the vessel intima or debris in the 
lesion (175). To investigate if Fatp1 alters MΦ’s ability to bind particles akin to oxidized LDL, 
10µM beads were used to model this behavior in thioglycollate-elicited peritoneal MΦs 
(176,177). Beads were allowed to bind for either 20 min or 60 minutes.  Adherent and engulfed 
beads were quantified for each time point (Supplemental Figure 3A-B). No significant 
differences were observed in adherent or engulfed beads at either time point. 
Discussion 
 
Increasingly, MΦ substrate metabolism has been shown to dictate inflammatory tone in 
complex ways as atherosclerotic lesions form and change over time (175). Increased glucose 
metabolism promotes pro-inflammatory cytokines and reactive oxygen species production (18). 
Classically- and alternatively-activated MΦs are detected in atherosclerotic lesions (178). The 
classical M1-like MΦ has been reported to be associated with plaque progression, while the 
immunosuppressive alternatively-activated M2-like phenotype is associated with smaller lesions 
and regression of plaques (108-114,179). We previously reported that pro-inflammatory 
activation is achievable by enhancing glucose metabolism via glucose transporter 1 (GLUT1) 
overexpression using an in vitro model - even in the absence of external stimuli (180) - in a 
demonstration of the tight immunometabolic link between MФ metabolic reprogramming and 
activation state. In contrast, increased fatty acid metabolism stimulates anti-inflammatory 
cytokine production or blunts pro-inflammatory activation (99,101,113). For example, 
upregulating FAO through inhibition of miR-33 can metabolically reprogram MΦs to the 
immunoregulatory AAM-like phenotype, and consequently promotes resolution of 
atherosclerosis (113). Our current study supports the notion that altering MΦ fatty acid 
metabolism can modulate inflammatory diseases such as atherosclerosis. A critical aspect of our 
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current work is that we demonstrate that specific deletion of FATP1 in monocyte-derived cells 
negatively regulates atherogenesis without disruption of systemic lipid metabolism.    
Metabolic reprogramming of MΦs offers a novel means of regulating inflammation in 
diseases ranging from diet induced obesity and insulin resistance to cancer (181,182). We 
previously reported that metabolism of fatty acids by FATP1 played a critical role in suppressing 
ATM-mediated inflammation and maintaining glucose tolerance (18). FATPs are expressed in 
tissues where lipid metabolism is central to the organ’s function, such as adipose tissue; or where 
lipids provide the predominant fuel, such heart and skeletal muscle (7,72,183). FATP1 activates 
long and very long chain FAs through its acyl-coA synthetase activity (74,79). Previous studies 
employing FATP1 total body knockout (Fatp1-/-) mice demonstrated decreased insulin 
resistance, abated intramuscular accumulation of fatty acyl-CoAs, and reduced rate of diet-
induced obesity when fed a high fat diet compared to Fatp1+/+ mice (33,81). Due to its complex 
expression pattern, the contribution of FATP1 to the development of metabolic dysfunction is 
likely to be tissue- and cell-type specific. Indeed, in contrast to the whole body Fatp1-/- mice, our 
lab reported that chimeras created by bone marrow transplantation were more susceptible to diet-
induced obesity and glucose intolerance compared to wild type transplanted mice without 
altering hematopoietic cell numbers (18). We also demonstrated that there was increased MΦ 
infiltration, inflammatory cytokine production, and oxidative stress in the adipose tissue of mice 
transplanted with Fatp1-/- marrow compared to Fatp1+/+ transplanted mice. Our published 
findings further support the varied cell-specific roles for FATP1 which may explain the observed 
discrepancy in phenotype between Fatp1-/- (33,81) and chimeric Fatp1B-/- mice (18). Thus Fatp1 
acts as a critical metabolic hub; allowing long chain fatty acid metabolism, which in turn 
  
76 
decreases glucose utilization (18) and associated inflammatory sequelae including oxidative 
stress. 
MΦs play a central role in the pathogenesis of atherosclerosis, hence we further 
questioned whether atherogenesis can be likewise modified by altering MΦ energy metabolism 
and thereby phenotypic state.  Through transplant of Fatp1-/- bone marrow into Ldlr-/- mice, we 
demonstrated a significant increase of atherosclerotic lesions in the absence of Fatp1 by en face 
analysis. Lesions in the aortic sinus were also almost two fold larger in Fatp1-/-Ldlr−/−mice 
compared to Fatp1+/+Ldlr−/−mice. These observed differences did not appear to be due to altered 
plaque necrosis, collagen deposition (i.e. plaque stability), or infiltration of cells into the 
subendothelial space including MΦs or SMCs.  Furthermore, Fatp1-/-Ldlr−/− and 
Fatp1+/+Ldlr−/−mice did not display significant differences in weight gain, glucose 
concentrations, or glucose tolerance on Western Diet. Importantly, plasma total cholesterol, LDL 
cholesterol, HDL cholesterol, and triacylglycerol concentrations also did not differ by Fatp1 
genotype. Thus, increased atherogenesis was not caused by impaired systemic lipid homeostasis 
but instead by increased local FATP1-dependent MΦ phenotypic changes. We next turned to an 
in vitro model  to examine FATP1’s contribution to macrophage’s binding and phagocytic 
capacity since this function is essential to lesion formation, stability, and regression (175). There 
were no detectable phagocytic differences driven by FATP1. In early lesions, MΦs become foam 
cells through engulfment of lipids, clearing neighboring dead cells (termed efferocytosis), and 
secretion of a spectrum of pro-inflammatory cytokines, ROS, and reactive nitrogen species 
(RNS). In advanced lesions, MΦs promote cell death, extracellular matrix degradation, and pro-
coagulation (28,169). Our findings suggest that FATP1 does not regulate phagocytosis but 
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regulates later macrophage functions including cytokine and ROS production, although the 
mechanisms remain unclear. 
Finally, we focused on the established role of FATP1 in maintaining the 
immunoregulatory AAM phenotype (18). FATP1 directs substrate metabolism in MΦs - when 
MΦs lack Fatp1, cells switch from oxidation of fatty acids to increased glucose utilization 
through elevated glycolysis, an indicator of a CAM/M1-like pro-inflammatory activation 
phenotype (18); when MΦs overexpressed Fatp1, cells displayed reduced glycolytic capacity and 
glucose oxidation, a marker of AAM/M2-like immunomodulatory phenotype (18). Our lab 
previously reported that RAW264.7 MΦs overexpressing Fatp1 secreted significantly less IL6 
compared to control MΦs, further demonstrating the importance of FATP1 in the regulation of 
MΦ phenotype (18) . In the current loss of function study, we detected significantly increased 
IL6 staining in aortic root lesions of Fatp1-/- Ldlr-/- mice, suggesting that FATP1 typically acts to 
limit inflammation and here lack of MΦ Fatp1 promoted lesion cytokine production. Our lab 
previously reported that Fatp1-/- MΦs expressed increased iNOS (Nos2) and TNFα (Tnfa), as 
well as significantly reduced arginase1 (Arg1) (18). Nitric oxide and TNFα accelerate 
atherogenesis (184), while the expression of arginase I (a marker of AAM/M2-like MΦs) 
decelerates atherogenesis (185). Expression of pro-inflammatory cytokines is often co-incident 
with oxidative damage.  In our previously published work, increased oxidative damage was 
detected in white adipose tissue of mice transplanted with Fatp1-/- marrow and made obese 
compared to mice transplanted with control Fatp1+/+ marrow. Importantly, herein we found that 
mice lacking MΦ Fatp1 displayed significantly increased 4HNE staining in the aortic root 
plaque, indicating that deletion of macrophage FATP1 exacerbated lesion oxidative stress. In 
conclusion, our data showed increased atherogenesis in Fatp1-/-Ldlr−/− mice, caused by deletion 
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of Fatp1-mediated local inflammation and oxidative stress compared to Fatp1+/+Ldlr−/− mice. 
However, several limitations to this study should be taken into account with regard to this work. 
First, our previous work studying FATP1 was in mice fed a high fat diet (18), which is different 
from the Western diet utilized herein and may limit comparisons across studies. Second, 
previous hematologic characterization of blood cells from Fatp1+/+ and Fatp1-/- mice (18) may 
inform atherosclerotic findings, yet future analysis is imperative specifically in mice lacking 
Fatp1 in the Ldlr-/- background to determine if the loss of FATP1 in the Ldlr-/- background alters 
the immune cell composition that may explain findings herein. Finally, we have extrapolated 
from previous work using typical stimuli (LPS/IFN or IL4) to model in vitro extremes of the 
MΦ polarization spectrum. Yet, it is possible that when macrophages are challenged with lipids 
such as oxidized or acetylated LDL or apoptotic foam cells which are more relevant to the 
atherosclerotic lesion, different phenotypes may emerge. Ideally, single cell RNA sequencing 
should be conducted on macrophages from lesions to best understand the in vivo phenotype and 
are planned for future studies.   
Our data provides new findings linking substrate utilization, macrophage function, and 
disease susceptibility in mouse models which implicate MΦ expression of Fatp1 as a critical 
mediator of these processes. Our hypothesis regarding MΦ FATP1 driving macrophage 
phenotype and atherosclerosis is difficult to prove in human studies but there are important clues 
that this may in fact be the case.  A common gene variant exists in SLC27A1 and is associated 
with elevated post-prandial lipemia and alterations in LDL particle size distribution (186). There 
are also reports of Fatp1 genomic variants affecting the levels of FATP1 mRNA, a putative cis-
eQTL, in the Metabolic Syndromes In Men (METSIM) study (18,187). More recent data from 
the GTEx portal indicates that there is complex, tissue-specific genetic regulation of FATP1 
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(188)  and a wider distribution of expression than originally understood. These data suggest that 
FATP1 expression varies in humans based on genotype and some FATP1 alleles are associated 
with cardiovascular disease related phenotypes. Further study specifically targeting macrophage 
metabolic phenotypes is needed to fully understand mechanisms linking fatty acid transport 












Figure. 3.1. Fatp1-/- Ldlr -/- mice displayed increased atherosclerotic lesion size compared to 
Fatp1+/+Ldlr-/- mice as determined by en face analysis.  (A) Fatp1+/+Ldlr-/- or Fatp1-/- Ldlr -/- 
aortas were isolated and stained with Oil red O. Representative images are shown. (B) 
Atherosclerotic lesion size was quantified using Image J software. Data are presented as means ± 




Figure. 3.2. Deletion of Fatp1 increased atherosclerotic lesions in the aorta sinus but not 
necrosis or collagen deposition.   (A) 20X representative photomicrographs of Oil Red O 
staining for Fatp1+/+Ldlr−/−or Fatp1-/-Ldlr−/− aortic sinus. (B) Atherosclerotic lesion size was 
quantified using Aperio ImageScope Software. (C) 20X representative photomicrographs of 
Masson’s trichrome staining for Fatp1+/+ Ldlr−/−or Fatp1-/-Ldlr−/− aortic sinus. (D) % necrotic 
area/total area in lesions was quantified using Aperio. (E) Collagen was quantified. (F) % 
subendothelial cell numbers/total area in subendothelial space were quantified. Data are 





Figure. 3.3. Fatp1-/-Ldlr−/− mice did not display alterations in plasma total cholesterol, LDL 
cholesterol, HDL cholesterol, and triacylglycerol concentrations compared to Fatp1+/+Ldlr−/− 
mice.   (A) Total cholesterol. (B) LDL cholesterol. (C) HDL cholesterol and (D) Triacylglyceride. 






Figure. 3.4. Deletion of Fatp1 increased atherosclerotic plaque oxidative stress without 
changing plaque cell composition.  (A) 200 µm representative images of immunostaining 
macrophage marker MOMA2.  (B) Quantification using OD x % MOMA2 positive staining.  (C) 
200 µm representative images of immunostaining SMC marker α-SMA. (D) Quantification using 
OD x % α-SMA positive staining. (E) 200 µm representative images of immunostaining oxidative 
stress marker 4HNE. (F) Quantification using OD x % 4HNE positive staining. *p=0.013. (G) 200 
µm representative images of immunostaining inflammation marker IL6.  (H) Quantification using 




Supplemental Figure. 3.1. Fatp1+/+ Ldlr−/− and Fatp1-/-Ldlr−/− displayed no differences in 
weight gain or body composition on Western Diet.   (A) Diagram of the study (B) Body weights 
were measured weekly starting at 5 weeks of age. (C) Fat mass percentage was measured by Echo 




Supplemental Figure. 3.2. Fatp1+/+ Ldlr−/− and Fatp1-/-Ldlr−/− displayed no differences in 
fasting plasma glucose or glucose tolerance. (A) 6 hour fasted glucose was measured at weeks 
indicated. (B) After 7 weeks on diet, GTT was performed and blood glucose was measured at 




Supplemental Figure. 3.3. Lack of MΦ Fatp1 did not significantly influence binding or 
engulfment of opsonized beads.  Thioglycollate-elicited peritoneal MΦs were incubated with 




 CHAPTER 4: SYNTHESIS 
Overview of findings 
 This dissertation focuses on two projects, which address the importance of acyl-CoA 
synthetase in skeletal muscle and macrophage. The purpose of the first project was to elucidate 
the role of ACSL1-mediated FAO in the pathogenesis of metabolic myopathy. The second 
project aimed to investigate the role of FATP1-mediated FA metabolism in macrophage.  
 Data discussed in Chapter 2 demonstrated that muscle ACSL1 is essential for skeletal 
muscle function and homeostasis in mice. We reported that compared to control mice, Acsl1M-/- 
mice run less and more slowly and have reduced muscle strength and coordination, suggesting an 
overall impairment of muscle function.  Lack of ACSL1 resulted in increased plasma CK and 
AST activity, indicating that ACSL1-deficient muscle was damaged. Because compared to 
controls, mitochondrial FAO was 90% lower in ACSL1-deficient muscle, we hypothesized that 
muscle from Acsl1M-/- mice would use more glucose. Contradictory to our hypothesis, glucose 
use did not increase in ACSL1-deficient muscle.  Skeletal muscle is the largest protein reservoir, 
so we focused on protein metabolism. Compared to controls, the protein synthesis rate was 2.1-
fold higher in glycolytic muscle from exercised Acsl1M-/- mice, suggesting an increase in protein 
turnover. We also reported increases in mitochondrial copy number and mRNA expression of 
FAO genes, which suggested that lack of ACSL1 resulted in a compensatory increase of FAO 
capacity in muscle, although FAO itself did not occur. Because ACSL1 was enriched on 
mitochondria, we examined how lack of ACSL1 affects muscle mitochondrial function and 
structure. Lack of ACSL1 did not change the capacity of isolated mitochondria from 
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Acsl1M-/- muscle to consume oxygen, although EM images showed an increased number of 
abnormal mitochondria. Unchanged mitochondrial function could be due to the isolation of only 
healthy mitochondria during isolation procedure. Our data revealed that ACSL1 plays an 
essential role in the maintenance of skeletal muscle function, metabolism, and mitochondrial 
structure.   
In Chapter 3 we reported that specific deletion of Fatp1 in macrophages negatively 
regulates atherogenesis without disrupting systemic lipid metabolism, highlighting the 
importance of FATP1 in suppressing atherosclerosis. FATP1-mediated FA metabolism promotes 
macrophage M2 polarization to an anti-inflammatory phenotype. We hypothesized that lack of 
macrophage FATP1 would increase atherogenesis. After transplantation of Fatp1+/+ and Fatp1-/- 
bone marrow into Ldlr-/- mice, we reported increases of atherosclerotic lesions in both aorta and 
aortic sinus from Fatp1-/- Ldlr-/- mice compared to control mice. We also assessed the 
inflammation status in the lesion microenvironment and reported that deletion of Fatp1 increases 
oxidative stress and inflammation in atherosclerotic plaques. However, lack of macrophage 
FATP1 does not change plaque necrosis, collagen deposition, or infiltration of cells into the 
subendothelial space. Plasma total cholesterol, LDL cholesterol, HDL cholesterol, triacylglycerol 
concentrations, body weight, glucose concentrations, and glucose tolerance are not changed. We 
concluded that increased atherogenesis is not caused by impaired systemic lipid homeostasis, but 
instead, by increased local FATP1-dependent macrophage phenotypic changes (157).  
Public Health Significance 
 
 Although metabolic myopathies are primarily rare genetic diseases, the symptoms of 
metabolic myopathy such as muscle weakness, pain, or exercise intolerance negatively affect life 
qualities.  Hence, studying the basic biology of metabolic myopathy is necessary to find a 
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strategy that can alleviate or prevent these symptoms. Acsl1M-/- mice developed disturbed FAO, 
muscle damage, and impaired exercise capacity and function, all of which mimic symptoms in 
patients with metabolic myopathies. Our data demonstrated that muscle FAO reduction was not 
associated with increased glucose use in Acsl1M-/- mice, in contrast to the result from the Cpt1bM-
/- metabolic myopathy mouse model (26). This finding is novel but valuable in that it suggests 
that dietary carbohydrate supplementation might not be able to prevent symptoms of metabolic 
myopathy from occurring in patients with defective FAO.  
 Atherosclerosis has very few treatment options; therefore, relevant research into 
biological mechanisms is necessary. Our data provide valuable information regarding how 
macrophage FA metabolism affects atherogenesis. Lack of FATP1 reduces FA uptake and FAO 
in macrophages (18). Mutated FATP1-mediated FA metabolism in macrophages increases lesion 
size in both aorta and aortic sinus in Ldlr-/- mice. These data are useful in that they suggest an 
important notion that macrophage FAO can limit the development of atherosclerotic lesions. Our 
data gathered information on how lack of FATP1 affects atherogenesis through a FATP1 loss-of-
function study. The question of whether overexpressing FATP1 in macrophages would limit 
atherogenesis remains unanswered. Our data show that FATP1 is a viable target to metabolically 
reprogram macrophages; however, FATP1 gain-of-function study is required to determine if 
FATP1 is a likely target for atherosclerosis prevention and treatment.  
Future Directions 
 
Effect of loss of ACSL1 on mTORC1 activation in Acsl1M-/- soleus 
 
Loss of ACSL1 in heart causes heart hypertrophy and mTORC1 pathway activation (3,5), 
but the result of ACSL1 absence differs in skeletal muscle.  Compared to controls, loss of 
ACSL1 did not change gastrocnemius weight and cell size. Accordingly, the mTORC1 pathway 
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was not upregulated in gastrocnemius. In contrast to gastrocnemius, loss of ACSL1 increased 
soleus weight and soleus cell size. Furthermore, increased TAG accumulation was present in 
soleus. It will be necessary to measure if loss of ACSL1 enhances activation of the mTORC1 
pathway in soleus. Activation of mTORC1 promotes cellular mRNA and protein synthesis. The 
future study will determine whether increased protein synthesis results in soleus weight and cell 
size enlargement.  
Effects of loss of ACSL1 in other muscle types 
Mouse skeletal muscle contains slow-twitch oxidative type I fibers, fast-twitch oxidative 
type IIA fibers, fast twitch glycolytic IIX fibers, and fast twitch glycolytic IIB fibers. Soleus is 
comprised of mostly type I and type IIA fibers; gastrocnemius contains mainly type IIX, type 
IIB, and type IA fibers; and diaphragm is primarily composed of type IIA fiber. This dissertation 
focused on the phenotypes of gastrocnemius and soleus. Our data demonstrated that loss of 
ACSL1 affects both muscle types, but the changes in gastrocnemius and soleus differ. Loss of 
ACSL1 caused muscle weight gain and TAG accumulation in soleus, whereas loss of ACSL1 
promoted mitochondria biogenesis and protein turnover in gastrocnemius. Because the fiber 
composition of diaphragm is different from soleus and gastrocnemius and undergoes constant 
involuntary contraction, while soleus and gastrocnemius stay relaxed most of time, it will be 
interesting to understand how loss of ACSL1 affects diaphragm.  
Effect of overexpression of macrophage FATP1 in atherosclerosis  
  
To determine if increased FATP1-mediated FA metabolism reduces atherosclerotic 
lesions, bone marrow containing macrophages that overexpress FATP1 should be transplanted to 
Ldlr-/- mice. To date, a macrophage FATP1 knock-in mouse is not available. However, 
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overexpression of FATP1 in macrophage cell line RAW264.7 reduces the inflammatory response 
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